

11/02/00  
jc957 U.S. PTO

11-06-00 A

Please type a plus sign (+) inside this box  +

Attorney Docket P1053R1D1  
PATENT

CERTIFICATION UNDER 37 CFR 1.10

EL 599 584 272 US Express Mail Number      November 2, 2000, Date of Deposit

I hereby certify that this Non-provisional Application Transmittal and the documents referred to as enclosed therein are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner of Patents, Washington, D.C. 20231.

  
Ann Savelli

jc957 U.S. PTO  
09/705579  
11/02/00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BOX PATENT APPLICATION  
Assistant Commissioner of Patents  
Washington, D.C. 20231

**NON-PROVISIONAL APPLICATION TRANSMITTAL UNDER 37 CFR 1.53(b)**

Transmitted herewith for filing is a non-provisional patent application:

Inventor(s) (or Application "Identifier"):

**Brian M. Fendly**

Title: **ANTI-ErbB2 ANTIBODIES**

**1. Type of Application**

- This application is for an original, non-provisional application.
- This is a non-provisional application claiming priority to provisional application no. \_\_\_, filed \_\_\_, the entire disclosure of which is hereby incorporated by reference.
- This is a  continuation-in-part  continuation  divisional application claiming priority to application Serial Number 08/948,192, filed October 9, 1997, the entire disclosure of which is hereby incorporated by reference.

**2. Papers Enclosed Which Are Required For Filing Date Under 37 CFR 1.53(b)  
(Non-provisional )**

61 pages of specification  
4 pages of claims  
1 page of abstract  
18 sheet(s) of drawings  
[x] formal  informal

**3. Declaration or Oath**

(for new and CIP applications; also for Cont./Div. where inventor(s) are being added)

An executed declaration of the inventor(s) [] is enclosed [] will follow.

(for Cont./Div. where inventorship is the same or inventor(s) being deleted)

A copy of the executed declaration/oath filed in the prior application is enclosed (37 CFR 1.63(d)).

(for Cont./Div. where inventor(s) being deleted)

A signed Petition and Statement is attached deleting inventors named in the prior application (see 37 CFR 1.63(d)(2) and 1.33(b)).

**4. Assignment**

(for new and CIP applications)

An Assignment of the invention to GENENTECH, INC. [] is enclosed with attached Recordation Form Cover Sheet [] will follow.

(for cont./div.)

The prior application is assigned of record to Genentech, Inc.

**5. Amendments (for continuation and divisional applications)**

Cancel in this application original claims \_\_\_ of the prior application before calculating the filing fee. (At least one original independent claim must be retained for filing purposes.)

A preliminary amendment is enclosed. (Claims added by this amendment have been properly numbered consecutively beginning with the number next following the highest numbered original claim in the prior application.)

**Relate Back -- 35 U.S.C. 120 or 35 U.S.C. 119**

Amend the specification by inserting before the first line the sentence:

--This is a

- non-provisional application  
 continuation  
 divisional  
 continuation-in-part

of co-pending application(s)

Serial No. \_\_ filed on \_\_, which application(s) is(are) incorporated herein by reference and to which application(s) priority is claimed under 35 USC §120. --

International Application \_\_ filed on \_\_ which designated the U.S., which application(s) is(are)

incorporated herein by reference and to which application(s) priority is claimed under 35 USC §120.--

\_\_\_\_\_ provisional application No. \_\_\_\_\_ filed \_\_\_, the entire disclosure of which is hereby incorporated by reference and to which application(s) priority is claimed under 35 USC §119.--.

#### 6. Fee Calculation (37 CFR 1.16)

The fee has been calculated as follows:

| CLAIMS FOR FEE CALCULATION          |    |              |   |            |                             |
|-------------------------------------|----|--------------|---|------------|-----------------------------|
| Number Filed                        |    | Number Extra |   | Rate       | Basic Fee<br>37 CFR 1.16(a) |
| Total Claims                        | 27 | - 20 =       | 7 |            | \$710.00                    |
| Independent Claims                  | 4  | - 3 =        | 1 | X \$18.00  | \$126.00                    |
| Multiple dependent claim(s), if any |    |              |   | + \$270.00 | \$0.00                      |
| <b>Filing Fee Calculation</b>       |    |              |   |            | <b>\$916.00</b>             |

#### 7. Method of Payment of Fees

The Commissioner is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$916.00. A duplicate copy of this transmittal is enclosed.

#### 8. Authorization to Charge Additional Fees

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR §1.16 and 1.17, or credit overpayment to Deposit Account No. 07-0630. A duplicate copy of this sheet is enclosed.

#### 9. Additional Papers Enclosed

- [X] Information Disclosure Statement (37 CFR §1.98) w/ PTO-1449 and -0- citations
- [X] Letter and Request to use Computer-Readable Sequence Listing
- Other:

#### 10. Maintenance of Copendency of Prior Application (for continuation and divisional applications)

*[This item must be completed and the necessary papers filed in the prior application if the period set in the prior application has run]*

- \_\_\_\_\_ A petition, fee and/or response has been filed to extend the term in the pending prior application until
- \_\_\_\_\_ A copy of the petition for extension of time in the **prior** application is attached.

**11. Correspondence Address:**

X Address all future communications to:

GENENTECH, INC.  
Attn: Wendy M. Lee  
1 DNA Way  
South San Francisco, CA 94080-4990  
(650) 225-1994

Respectfully submitted,  
GENENTECH, INC.

By:   
Wendy M. Lee  
Reg. No. 40,378

Date: November 2, 2000

1 DNA Way  
So. San Francisco, CA 94080-4990  
Phone: (650) 225-1994  
Fax: (650) 952-9881

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

|                              |   |  |
|------------------------------|---|--|
| Brian M. Fendly              | Group Art Unit: not yet assigned  |  |
| Serial No.: not yet assigned | Examiner: not yet assigned  |  |
| Filed: November 2, 2000      | <b>CERTIFICATE OF EXPRESS MAILING</b>   |  |
| For: ANTI-ErbB2 ANTIBODIES   | I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post to Addressee" service under 37 CFR 1.10 on the date indicated below and is addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231. |  |
|                              | Express Mail Label No. EL 599 584 272 US  |  |
|                              | November 2, 2000  |  |
|                              | <br>Ann Savelli  |  |

**PRELIMINARY AMENDMENT**

Assistant Commissioner of Patents  
Washington, D.C. 20231

Sir:

**IN THE SPECIFICATION:**

Please delete lines 11-13 on page 1 and insert --This is a divisional of USSN 08/948,192 filed 10/09/97 which claims priority under USC Section 119(e) to provisional application Serial No. 60/028,811 filed 10/18/96 the disclosure of which is incorporated herein by reference.--

On page 2, line 16, replace "Fukushigi" with --Fukushige--.

On page 2, line 17, replace "Geurin" with --Guerin--.

On page 2, line 20, replace "354-357" with --254-257--.

On page 2, line 21, replace "Pathobiology" with --Pathobiology--.

On page 5, line 28, replace "235-257" with --235-237--.

On page 20, line 9, please replace "Cytoxin, Taxol, Toxotere" with --Cytoxan, Taxol, Taxotere--.

On page 20, line 11, please replace "Vincreistine" with --Vincristine--.

On page 49, line 16, please replace “ling” with --lung--.

On page 51, line 12, please delete “12301 Parklawn Drive, Rockville, MD” and insert --10801 University Blvd., Manassas, VA20110-2209--.

On page 53, line 12, replace “Darzynkiewica” with --Darzynkiewicz--.

On page 53, line 22, replace “Fracker” with - -Fraker--.

IN THE CLAIMS:

Please delete claims 1-41 and add new claims 42-68.

--42. (NEW) A method of treating a tumor or cancer characterized by overexpression or activation of ErbB2 comprising administering an anti-ErbB2 antibody to a patient in an amount effective to kill or inhibit growth of tumor cells in the patient, wherein the tumor or cancer is selected from the group consisting of a liver tumor, colorectal tumor, prostate tumor, pancreatic tumor, vulval tumor, thyroid tumor, hepatic tumor, sarcoma, glioblastoma, head and neck tumor, leukemia and lymphoid malignancy.

43. (NEW) The method of claim 42 wherein the tumor or cancer is a liver tumor.

44. (NEW) The method of claim 42 wherein the tumor or cancer is a colorectal tumor.

45. (NEW) The method of claim 42 wherein the tumor or cancer is a prostate tumor.

46. (NEW) The method of claim 42 wherein the tumor or cancer is a pancreatic tumor.

47. (NEW) The method of claim 42 wherein the tumor or cancer is a vulval tumor.

48. (NEW) The method of claim 42 wherein the tumor or cancer is a thyroid tumor.

49. (NEW) The method of claim 42 wherein the tumor or cancer is a hepatic tumor.

50. (NEW) The method of claim 42 wherein the tumor or cancer is a sarcoma.

51. (NEW) The method of claim 42 wherein the tumor or cancer is a glioblastoma.
52. (NEW) The method of claim 42 wherein the tumor or cancer is a head and neck tumor.
53. (NEW) The method of claim 42 wherein the tumor or cancer is leukemia.
54. (NEW) The method of claim 42 wherein the tumor or cancer is a lymphoid malignancy.
55. (NEW) The method of claim 42 wherein the anti-ErbB2 antibody cross-blocks binding of antibody 4D5 (ATCC CRL 10463) to ErbB2.
56. (NEW) The method of claim 42 wherein the anti-ErbB2 antibody cross-blocks binding of antibody 7C2 (ATCC HB-12215) or antibody 7F3 (ATCC HB-12216) to ErbB2.
57. (NEW) The method of claim 42 further comprising combining a second therapeutic regimen with the administration of the anti-ErbB2 antibody.
58. (NEW) The method of claim 57 wherein the second therapeutic regimen is selected from the group consisting of (a) administration to the patient of a chemotherapeutic agent, anti-estrogen compound, anti-progesterone compound, an antibody against a tumor associated antigen other than ErbB2, a second different anti-ErbB2 antibody, a cytokine or a growth inhibitory agent in an amount effective to kill or inhibit growth of tumor cells in the patient, and (b) radiation therapy.
59. (NEW) The method of claim 58 wherein the second therapeutic regimen comprises administration to the patient of a chemotherapeutic agent in an amount effective to kill or inhibit growth of tumor cells in the patient.
60. (NEW) The method of claim 59 wherein the chemotherapeutic agent is selected from the group consisting of Doxorubicin, 5-Fluorouracil, Cytosine arabinoside ("Ara-C"), Cyclophosphamide, Thiotepa, Busulfan, Cytoxin, Methotrexate, Cisplatin, Melphalan, Vinblastine,

Bleomycin, Etoposide, Ifosfamide, Mitomycin C, Mitoxantrone, Vincristine, Vinorelbine, Carboplatin, Teniposide, Daunomycin, Carminomycin, Aminopterin, Dactinomycin, Mitomycins, Esperamicins, Melphalan and other related nitrogen mustards, tamoxifen and onapristone.

61. (NEW) The method of claim 57 wherein the second therapeutic regimen comprises administration to the patient of a growth inhibitory agent in an amount effective to inhibit growth of tumor cells in the patient.

62. (NEW) The method of claim 61 wherein the growth inhibitory agent is selected from the group consisting of vincas, topo II inhibitors, doxorubicin, daunorubicin, etoposide, bleomycin, DNA alkylating agents, tamoxifen, prednisone, dacarbazine, mechlorethamine, cisplatin, methotrexate, 5-fluorouracil, and ara-C.

63. (NEW) A method of treating a tumor or cancer characterized by overexpression or activation of ErbB2 comprising a first therapeutic regimen comprising administering an anti-ErbB2 antibody to a patient in an amount effective to kill or inhibit growth of tumor cells in the patient and a second therapeutic regimen comprising administering a growth inhibitory agent in an amount effective to inhibit growth of tumor cells in the patient, wherein the growth inhibitory agent is a vinca.

64. (NEW) The method of claim 63 wherein the vinca is selected from the group consisting of Vincristine, Vinblastine and Vinorelbine.

65. (NEW) The method of claim 63 wherein the anti-ErbB2 antibody cross-blocks binding of antibody 4D5 (ATCC CRL 10463) to ErbB2.

66. (NEW) The method of claim 63 wherein the anti-ErbB2 antibody cross-blocks binding of antibody 7C2 (ATCC HB-12215) or antibody 7F3 (ATCC HB-12216) to ErbB2.

67. (NEW) An article of manufacture comprising a container with an anti-ErbB2 antibody contained within the container and a label which indicates that the anti-ErbB2 can be used to treat a

tumor or cancer characterized by overexpression or activation of ErbB2, wherein the tumor is selected from the group consisting of a liver tumor, colorectal tumor, prostate tumor, pancreatic tumor, vulval tumor, thyroid tumor, hepatic tumor, sarcoma, glioblastoma, head and neck tumor, leukemia and lymphoid malignancy.

68. (NEW) An article of manufacture comprising a container with an anti-ErbB2 antibody contained within the container and a label which indicates that the anti-ErbB2 antibody can be combined with a growth inhibitory agent to treat a tumor or cancer characterized by overexpression or activation of ErbB2, wherein the growth inhibitory agent is a vinca--

#### REMARKS

The specification is amended herein to update the claim to priority, fix typographical errors and add the new ATCC address.


Claims 1-41 have been replaced by claims 42-68 herein which find specification basis *at least* as follows:

claim 42 - page 49, lines 12-17 and page 7, lines 1-20  
claims 43-54 - page 49, lines 15-17  
claims 55 and 65 - page 13, lines 1-7  
claims 56 and 66 - page 12, lines 24-31; page 51, lines 14-15  
claim 57 - page 49, lines 25-26  
claim 58 - page 49, lines 25-28 and page 50, lines 2-13  
claim 59 - page 49, lines 27-28  
claim 60 - page 20, lines 7-14  
claim 61 - page 50, lines 8-9  
claim 62 - page 20, lines 15-24  
claim 63 - page 49, line 12 through to line 13 on page 50 and page 20, line 20  
claim 64 - page 20, lines 10-11 and 20  
claim 67 - new claim 42 and original claim 41  
claim 68 - new claim 63 and original claim 41

In that the amendments do not introduce new matter their entry is respectfully requested.

Date: November 2, 2000

By:



Wendy M. Lee  
Reg. No. 40,378

1 DNA Way  
So. San Francisco, CA 94080-4990  
Phone: (650) 225-1000  
Fax: (650) 952-9881

5

ANTI-ErbB2 ANTIBODIES

10

**BACKGROUND OF THE INVENTION**

This is a non-provisional application filed under 37 CFR 1.53(b)(1), claiming priority under USC Section 119(e) to provisional Application Serial No. 60/028,811, filed on 18 October 1996.

15

**Field of the Invention**

This invention relates generally to antibodies which bind the ErbB2 receptor. In particular, it pertains to anti-ErbB2 antibodies which bind to an epitope in Domain 1 of ErbB2 and induce cell death via apoptosis.

20

**Description of Related Art**

Transduction of signals that regulate cell growth and differentiation is modulated in part by phosphorylation of various cellular proteins. Protein tyrosine kinases are enzymes that are involved in this process. Receptor protein tyrosine kinases are believed to direct cellular growth via ligand-stimulated tyrosine phosphorylation of intracellular substrates. The class I subfamily of growth factor receptor protein tyrosine kinases includes the 170 kDa epidermal growth factor receptor (EGFR) encoded by the *erbB1* gene. *erbB1* has been causally implicated in human malignancy. In particular, increased expression of this gene has been observed in carcinomas of the breast, bladder, lung, head, neck and stomach. Monoclonal antibodies directed against the EGFR have been evaluated as therapeutic agents in the treatment of such malignancies.

25

For a review, see Baselga *et al.* *Pharmac. Ther.* 64:127-154 (1994). See also Masui *et al.* *Cancer Research* 44:1002-1007 (1984).

Wu *et al.* *J. Clin. Invest.* 95:1897-1905 (1995) recently report that the anti-EGFR monoclonal antibody (mAb) 225 (which competitively inhibits EGF binding and blocks activation

of this receptor) could induce the human colorectal carcinoma cell line DiFi (which expresses high levels of EGFR) to undergo G<sub>1</sub> cell cycle arrest and programmed cell death (apoptosis). Addition of IGF-1 or high concentrations of insulin could delay apoptosis induced by mAb 225, whereas G<sub>1</sub> arrest could not be reversed by addition of IGF-1 or insulin.

The second member of the class I subfamily, p185<sup>neu</sup>, was originally identified as the product of the transforming gene from neuroblastomas of chemically treated rats. The activated form of the *neu* protooncogene results from a point mutation (valine to glutamic acid) in the transmembrane region of the encoded protein. Amplification of the human homolog of *neu* (called erbB2 or HER2) is observed in breast and ovarian cancers and correlates with a poor prognosis (Slamon et al., *Science*, 235:177-182 (1987); and Slamon et al., *Science*, 244:707-712 (1989)). Accordingly, Slamon et al. in US Pat No. 4,968,603 describe various diagnostic assays for determining erbB2 gene amplification or expression in tumor cells. To date, no point mutation analogous to that in the *neu* protooncogene has been reported for human tumors. Overexpression (frequently but not uniformly due to amplification) of erbB2 has also been observed in other carcinomas including carcinomas of the stomach, endometrium, salivary gland, lung, kidney, colon, thyroid, pancreas and bladder. See, among others, King et al., *Science*, 229:974 (1985); Yokota et al., *Lancet*: 1:765-767 (1986); Fukushige et al., *Mol Cell Biol.*, 6:955-958 (1986); Geurin et al., *Oncogene Res.*, 3:21-31 (1988); Cohen et al., *Oncogene*, 4:81-88 (1989); Yonemura et al., *Cancer Res.*, 51:1034 (1991); Borst et al., *Gynecol. Oncol.*, 38:364 (1990); Weiner et al., *Cancer Res.*, 50:421-425 (1990); Kern et al., *Cancer Res.*, 50:5184 (1990); Park et al., *Cancer Res.*, 49:6605 (1989); Zhai et al., *Mol. Carcinog.*, 3:354-357 (1990); Aasland et al. *Br. J. Cancer* 57:358-363 (1988); Williams et al. *Pathobiology* 59:46-52 (1991); and McCann et al., *Cancer*, 65:88-92 (1990).

Antibodies directed against the rat *neu* and human erbB2 protein products have been described. Drebin et al., *Cell* 41:695-706 (1985) refer to an IgG2a monoclonal antibody which is directed against the rat *neu* gene product. This antibody called 7.16.4 causes down-modulation of cell surface p185 expression on B104-1-1 cells (NIH-3T3 cells transfected with the *neu* protooncogene) and inhibits colony formation of these cells. Drebin et al. say at page 699 that the antibody exerts a cytostatic effect rather than an irreversible cytotoxic effect on *neu*-transformed cells in soft agar. In Drebin et al. *PNAS (USA)* 83:9129-9133 (1986), the 7.16.4 antibody was shown to inhibit the tumorigenic growth of *neu*-transformed NIH-3T3 cells as well as rat neuroblastoma cells (from which the *neu* oncogene was initially isolated) implanted into

nude mice. Drebin *et al.* in *Oncogene* 2:387-394 (1988) discuss the production of a panel of antibodies against the rat *neu* gene product. All of the antibodies were found to exert a cytostatic effect on the growth of *neu*-transformed cells suspended in soft agar. Antibodies of the IgM, IgG2a and IgG2b isotypes were able to mediate significant *in vitro* lysis of *neu*-transformed cells in the presence of complement, whereas none of the antibodies were able to mediate high levels of antibody-dependent cellular cytotoxicity (ADCC) of the *neu*-transformed cells. Drebin *et al.* *Oncogene* 2:273-277 (1988) report that mixtures of antibodies reactive with two distinct regions on the p185 molecule result in synergistic anti-tumor effects on *neu*-transformed NIH-3T3 cells implanted into nude mice. Biological effects of anti-*neu* antibodies are reviewed in Myers *et al.*, *Meth. Enzym.* 198:277-290 (1991). See also WO94/22478 published October 13, 1994.

Hudziak *et al.*, *Mol. Cell. Biol.* 9(3):1165-1172 (1989) describe the generation of a panel of anti-ErbB2 antibodies which were characterized using the human breast tumor cell line SKBR3. Relative cell proliferation of the SKBR3 cells following exposure to the antibodies was determined by crystal violet staining of the monolayers after 72 hours. Using this assay, maximum inhibition was obtained with the antibody called 4D5 which inhibited cellular proliferation by 56%. Other antibodies in the panel, including 7C2 and 7F3, reduced cellular proliferation to a lesser extent in this assay. Hudziak *et al.* conclude that the effect of the 4D5 antibody on SKBR3 cells was cytostatic rather than cytotoxic, since SKBR3 cells resumed growth at a nearly normal rate following removal of the antibody from the medium. The antibody 4D5 was further found to sensitize p185<sup>erbB2</sup>-overexpressing breast tumor cell lines to the cytotoxic effects of TNF- $\alpha$ . See also WO89/06692 published July 27, 1989. The anti-ErbB2 antibodies discussed in Hudziak *et al.* are further characterized in Fendly *et al.* *Cancer Research* 50:1550-1558 (1990); Kotts *et al.* *In Vitro* 26(3):59A (1990); Sarup *et al.* *Growth Regulation* 1:72-82 (1991); Shepard *et al.* *J. Clin. Immunol.* 11(3):117-127 (1991); Kumar *et al.* *Mol. Cell. Biol.* 11(2):979-986 (1991); Lewis *et al.* *Cancer Immunol. Immunother.* 37:255-263 (1993); Pietras *et al.* *Oncogene* 9:1829-1838 (1994); Vitetta *et al.* *Cancer Research* 54:5301-5309 (1994); Sliwkowski *et al.* *J. Biol. Chem.* 269(20):14661-14665 (1994); Scott *et al.* *J. Biol. Chem.* 266:14300-5 (1991); and D'souza *et al.* *Proc. Natl. Acad. Sci.* 91:7202-7206 (1994).

Tagliabue *et al.* *Int. J. Cancer* 47:933-937 (1991) describe two antibodies which were selected for their reactivity on the lung adenocarcinoma cell line (Calu-3) which overexpresses ErbB2. One of the antibodies, called MGR3, was found to internalize, induce phosphorylation of ErbB2, and inhibit tumor cell growth *in vitro*.

McKenzie et al. *Oncogene* 4:543-548 (1989) generated a panel of anti-ErbB2 antibodies with varying epitope specificities, including the antibody designated TA1. This TA1 antibody was found to induce accelerated endocytosis of ErbB2 (see Maier et al. *Cancer Res.* 51:5361-5369 (1991)). Bacus et al. *Molecular Carcinogenesis* 3:350-362 (1990) reported that the TA1 antibody induced maturation of the breast cancer cell lines AU-565 (which overexpresses the erbB2 gene) and MCF-7 (which does not). Inhibition of growth and acquisition of a mature phenotype in these cells was found to be associated with reduced levels of ErbB2 receptor at the cell surface and transient increased levels in the cytoplasm.

Stancovski et al. *PNAS (USA)* 88:8691-8695 (1991) generated a panel of anti-ErbB2 antibodies, injected them i.p. into nude mice and evaluated their effect on tumor growth of murine fibroblasts transformed by overexpression of the erbB2 gene. Various levels of tumor inhibition were detected for four of the antibodies, but one of the antibodies (N28) consistently stimulated tumor growth. Monoclonal antibody N28 induced significant phosphorylation of the ErbB2 receptor, whereas the other four antibodies generally displayed low or no phosphorylation-inducing activity. The effect of the anti-ErbB2 antibodies on proliferation of SKBR3 cells was also assessed. In this SKBR3 cell proliferation assay, two of the antibodies (N12 and N29) caused a reduction in cell proliferation relative to control. The ability of the various antibodies to induce cell lysis *in vitro* via complement-dependent cytotoxicity (CDC) and antibody-mediated cell-dependent cytotoxicity (ADCC) was assessed, with the authors of this paper concluding that the inhibitory function of the antibodies was not attributed significantly to CDC or ADCC.

Bacus et al. *Cancer Research* 52:2580-2589 (1992) further characterized the antibodies described in Bacus et al. (1990) and Stancovski et al. of the preceding paragraphs. Extending the i.p. studies of Stancovski et al., the effect of the antibodies after i.v. injection into nude mice harboring mouse fibroblasts overexpressing human ErbB2 was assessed. As observed in their earlier work, N28 accelerated tumor growth whereas N12 and N29 significantly inhibited growth of the ErbB2-expressing cells. Partial tumor inhibition was also observed with the N24 antibody. Bacus et al. also tested the ability of the antibodies to promote a mature phenotype in the human breast cancer cell lines AU-565 and MDA-MB453 (which overexpress ErbB2) as well as MCF-7 (containing low levels of the receptor). Bacus et al. saw a correlation between tumor inhibition *in vivo* and cellular differentiation; the tumor-stimulatory antibody N28 had no effect on differentiation, and the tumor inhibitory action of the N12, N29 and N24 antibodies correlated with the extent of differentiation they induced.

Xu et al. *Int. J. Cancer* 53:401-408 (1993) evaluated a panel of anti-ErbB2 antibodies for their epitope binding specificities, as well as their ability to inhibit anchorage-independent and anchorage-dependent growth of SKBR3 cells (by individual antibodies and in combinations), modulate cell-surface ErbB2, and inhibit ligand stimulated anchorage-independent growth. See also WO94/00136 published Jan 6, 1994 and Kasprzyk et al. *Cancer Research* 52:2771-2776  
5 (1992) concerning anti-ErbB2 antibody combinations. Other anti-ErbB2 antibodies are discussed in Hancock et al. *Cancer Res.* 51:4575-4580 (1991); Shawver et al. *Cancer Res.* 54:1367-1373 (1994); Arteaga et al. *Cancer Res.* 54:3758-3765 (1994); and Harwerth et al. *J. Biol. Chem.* 267:15160-15167 (1992).

A further gene related to erbB2, called erbB3 or HER3, has also been described. See,  
10 e.g., US Pat. Nos. 5,183,884 and 5,480,968. ErbB3 is unique among the ErbB receptor family in that it possesses little or no intrinsic tyrosine kinase activity. However, when ErbB3 is co-expressed with ErbB2, an active signaling complex is formed and antibodies directed against ErbB2 are capable of disrupting this complex (Sliwkowski et al., *J. Biol. Chem.*, 269(20):14661-14665 (1994)). Additionally, the affinity of ErbB3 for heregulin (HRG) is increased to a higher  
15 affinity state when co-expressed with ErbB2. See also, Levi et al., *Journal of Neuroscience* 15: 1329-1340 (1995); Morrissey et al., *Proc. Natl. Acad. Sci. USA* 92: 1431-1435 (1995); and Lewis et al., *Cancer Res.*, 56:1457-1465 (1996) with respect to the ErbB2-ErbB3 protein complex.

The class I subfamily of growth factor receptor protein tyrosine kinases has been further extended to include the HER4/p180<sup>erbB4</sup> receptor. See EP Pat Appln No 599,274; Plowman et al., *Proc. Natl. Acad. Sci. USA*, 90:1746-1750 (1993); and Plowman et al., *Nature*, 366:473-475 (1993). Plowman et al. found that increased HER4 expression correlated with certain carcinomas of epithelial origin, including breast adenocarcinomas. This receptor, like ErbB3, forms an active signalling complex with ErbB2 (Carraway and Cantley, *Cell* 78:5-8 (1994)).

The quest for an ErbB2 activator has lead to the discovery of a family of heregulin polypeptides. These proteins appear to result from alternative splicing of a single gene and are called neuregulins (NRGs), neu differentiation factors (NDFs), heregulins (HRGs), glial growth factors (GGFs) and acetylcholine receptor inducing activity (ARIA) in the literature. For a review, see Groenen et al. *Growth Factors* 11:235-257 (1994); Lemke, G. *Molec. & Cell. Neurosci.* 7:247-262 (1996) and Lee et al. *Pharm. Rev.* 47:51-85 (1995).

## SUMMARY OF THE INVENTION

This invention relates, at least in part, to the surprising discovery that certain anti-ErbB2 antibodies can induce death of an ErbB2 overexpressing cell (e.g. a BT474, SKBR3 or Calu 3 cell) via apoptosis. In contrast to the apoptotic anti-EGFR antibody described in Wu *et al.*, *J. Clin. Invest.* 95:1897-1905 (1995), the anti-ErbB2 antibodies of interest herein are not thought to induce apoptosis by disruption of an autocrine loop. Antibodies herein with these cell death-inducing attributes will normally bind to a region in the extracellular domain of ErbB2, e.g. to an epitope in Domain 1 of ErbB2. Preferably, the antibodies will bind to the ErbB2 epitope bound by the 7C2 and/or 7F3 antibodies described herein.

Preferred antibodies are monoclonal antibodies e.g. humanized antibodies. Antibodies of particular interest are those which, in addition to the above-described properties, bind the ErbB2 receptor with an affinity of at least about 10nM, more preferably at least about 1nM.

In certain embodiments, the antibody is immobilized on (e.g. covalently attached to) a solid phase, e.g. for affinity purification of the receptor or for diagnostic assays. For diagnostic uses, it may also be beneficial to provide a labelled antibody (*i.e.* the antibody bound to a detectable label).

The antibodies of the preceding paragraphs may be provided in the form of a composition comprising the antibody and a pharmaceutically acceptable carrier or diluent. Optionally, the composition further comprises a second anti-ErbB2 antibody, especially where the second anti-ErbB2 antibody is one which binds to an epitope on the ErbB2 receptor which differs from that to which the 7C2/7F3 antibodies disclosed herein bind. In a preferred embodiment, the second antibody is one which inhibits growth of SKBR3 cells in cell culture by 50%-100% (*i.e.* 4D5 antibody and functional equivalents thereof). The composition for therapeutic use will be sterile and may be lyophilized.

The invention also provides: an isolated nucleic acid molecule encoding the antibody of the preceding paragraphs which may further comprise a promoter operably linked thereto; an expression vector comprising the nucleic acid molecule operably linked to control sequences recognized by a host cell transformed with the vector; a host cell comprising the nucleic acid (e.g. a hybridoma cell line); and a process for making the antibody comprising culturing a cell comprising the nucleic acid so as to express the anti-ErbB2 antibody and, optionally, recovering the antibody from the host cell culture and, preferably, the host cell culture medium.

The invention also provides methods for using the anti-ErbB2 antibodies disclosed

herein. For example, the invention provides a method for inducing cell death comprising exposing a cell, such as a cancer cell which overexpresses ErbB2, to anti-ErbB2 antibody described herein in an amount effective to induce cell death. The cell may be in cell culture or in a mammal, e.g. a mammal suffering from cancer. The invention also provides a method for inducing apoptosis of a cell which overexpresses ErbB2 comprising exposing the cell to exogenous anti-ErbB2 antibody as described herein in an amount effective to induce apoptosis of the cell. Thus, the invention provides a method for treating a mammal suffering from a condition characterized by overexpression of the ErbB2 receptor, comprising administering a pharmaceutically effective amount of the anti-ErbB2 antibodies disclosed herein to the mammal. According to any of the above methods, a further anti-ErbB2 antibody may be used, especially one which binds to a different ErbB2 epitope from that to which the 7C2/7F3 antibodies disclosed herein bind (e.g. one that does not bind Domain 1). In one embodiment, the second antibody inhibits growth of SKBR3 cells in cell culture by 50%-100% and optionally binds to the epitope on ErbB2 to which 4D5 binds.

In Example 2 below, it was found that the pro-apoptotic antibody 7C2 almost completely eradicated the entire culture of growth arrested cells. Therefore, it may be desirable to combine the pro-apoptotic antibodies disclosed herein with a growth inhibitory agent in the *in vitro* and *in vivo* methods discussed above. In such embodiments, superior levels of apoptosis may be achieved by administering the growth inhibitory agent prior to the pro-apoptotic anti-ErbB2 antibody. However, simultaneous administration or administration of the anti-ErbB2 antibody first is also contemplated.

The invention also provides an article of manufacture for use in the above *in vivo* methods which comprises a container holding the anti-ErbB2 antibody and a label on or associated with the container which indicates that the antibody can be used to treat conditions characterized by ErbB2 overexpression, such as cancer.

In a further aspect, the invention provides a method for detecting ErbB2 *in vitro* or *in vivo* comprising contacting the antibody with a cell suspected of containing ErbB2 and detecting if binding has occurred. Accordingly, the invention provides an assay for detecting a tumor characterized by amplified expression of ErbB2 comprising the steps of exposing a cell to the antibody disclosed herein and determining the extent of binding of the antibody to the cell. Preferably the antibody for use in such an assay will be labelled and will be supplied in the form of a kit with instructions for using the antibody to detect ErbB2. The assay herein may be an *in*

*vitro* assay (such as an ELISA assay) or an *in vivo* assay. For *in vivo* tumor diagnosis, the antibody is preferably conjugated to a radioactive isotope and administered to a mammal, and the extent of binding of the antibody to tissues in the mammal is observed by external scanning for radioactivity.

5

### Brief Description of the Drawings

Figs. 1A & B show the effects of apoptosis on a cell and a method for determining apoptosis, respectively. Fig. 1A shows the physiological changes which occur to a cell which undergoes programmed cell death (apoptosis). Fig. 1B shows translocation of phosphatidyl serine (PS) from the inner leaflet of the plasma membrane to the exterior of the cell. This PS translocation process is specific for cells undergoing apoptosis. Annexin V binds specifically to PS and thus provides a means for determining apoptosis.

Fig. 2 shows the epitope specificity of anti-ErbB2 antibodies. MAbs were used to block the binding of 7C2 to BT474 cells. BT474 cells ( $0.5 \times 10^6$ ) pretreated or not with 50 $\mu$ g anti-ErbB2 antibodies (15 minutes on ice) were washed twice, resuspended in 0.1ml 1% FBS/PBS and incubated with 5 $\mu$ g of fluorescein isothiocyanate (FITC) conjugated 7C2 antibody (15 minutes on ice). Following incubation, the cell suspensions were washed twice with 1% FBS/PBS to remove unbound fluorochrome, fixed with 1% paraformaldehyde/PBS and analyzed by flow cytometry.

Figs. 3A-D depict the effect of anti-ErbB2 antibodies on human breast cancer cells which overexpress ErbB2. Cells with normal membrane functions at the time of harvest ("viable" cells) exclude the DNA dye 7AAD and after membrane permeabilization are stained preferentially with Hoechst. Analysis of these cells reveals a classic DNA profile (far right panels) with cells in the G<sub>0</sub>/G<sub>1</sub> phase (major peak) and S-G<sub>2</sub>-M phase (indicated with double headed arrow) of the cell cycle. In the center panels, the population of cells indicated by the arrow represent dead cells, some of which had abnormal permeability characteristics at the time of harvest and had degraded their nuclear DNA.  $4 \times 10^4$  BT474 cells/ml were incubated for 72 hours in medium containing an isotype-matched control Ig (Fig. 3A), 1 $\mu$ g of monoclonal 4D5 (Fig. 3B), 50 $\mu$ g of monoclonal 7C2 (Fig. 3C), or 1 $\mu$ g 4D5 antibody + 50 $\mu$ g 7C2 antibody (Fig. 3D). The percentage of dead cells is indicated in the middle panels (7AAD fluorescence vs. Hoechst fluorescence) and the percentage of viable cells in the combined S, G<sub>2</sub>, and M phases of the cell cycle is indicated in the right panels (Hoechst fluorescence vs. cell count). The lefthand panel shows the size of the cells as determined by forward and right angle light scatter.

Figs. 4A & B reveal the additive effect of 4D5 and 7C2 antibodies on DNA synthesis, and viability in BT474 cells. The average of two experiments  $\pm$  S.D. is shown. In Fig. 4A,  $8 \times 10^3$  cells/0.2 ml/well were treated with 4D5 (0.05 $\mu$ g/ml) and/or 7C2 (50 $\mu$ g/ml) for 72 hours and pulsed for the last 12 hours with 1 $\mu$ Ci [ $^3$ H]-thymidine (in triplicate). In Fig. 4B, for cell viability, a total cell count was obtained and viability was determined by FACS analysis. The standard deviation for both 7C2 and 7C2 plus 4D5 treatment is too small ( $1 \times 10^3$  cells) to be seen in the figure.

Figs. 5A-F show induction of apoptosis by anti-ErbB2 MAbs 7C2 and 4D5 in BT474 breast tumor cells. Figs. 5A, 5C and 5E show plots of forward scatter (FS), an indicator of cell size, vs. log FITC (representing annexin V binding). Figs. 5B, D and F are quadrant plots of log FITC vs. log propidium iodine (PI), with percent annexin V-positive cells shown in quadrant 4 and percent annexin V/PI positive cells in quadrant 2. Untreated cells display a uniform size and fluorescence signal, as seen within the drawn circle, and are 85% viable (Fig. 5A). In addition to displaying low annexin V-binding, these cells do not take up PI, indicating no change in membrane integrity. Treatment for 3 days with 10 $\mu$ g/ml MAb 7C2 results in a reduction in the percent of viable cells (to 25.3 %, Fig. 5E) and a shift of almost the entire population to a smaller, FITC-positive population of cells (Fig. 5E). As shown in Fig. 5F, MAb 7C2 induces a 7-8 fold increase in the percent of annexin V-positive/PI-positive cells, indicating apoptotic cell death. The anti-proliferative MAb, 4D5, induces a small degree of apoptosis (2.5 fold above control, Figs. 5C and D).

Fig. 6 shows that the effects of MAb 7C2 are dose-dependent. The induction of apoptosis in BT474 breast tumor cells by MAb 7C2, as measured by an increase in the number of annexin V-positive and PI-positive cells, is apparent at a concentration of 0.1 $\mu$ g/ml and reaches a maximum at 1 $\mu$ g/ml.

Figs. 7A and 7B are time-courses of MAb 7C2-induced apoptosis in BT474 and SKBR3 breast tumor cells, respectively. Treatment of BT474 cells (Fig. 7A) and SKBR3 cells (Fig 7B) with 10 $\mu$ g/ml MAb 7C2 results in a reduction in the percent of viable cells (those cells which are annexin V- and PI-negative) as early as 15 minutes after initiation of treatment and reaches a maximum at 24 hours. The BT474 cell line is more sensitive to the pro-apoptotic effect of MAb 7C2 compared to the SKBR3 cells.

Figs 8A-E show responses of different cell lines to anti-ErbB2 MAbs. The BT474, SKBR3 and MCF7 breast tumor cell lines, and normal human mammary epithelial cells (HMEC) (Figs. 8A-D, respectively) were incubated with the anti-ErbB2 MAbs 4D5, 3H4, 7F3, 7C2, 2H11, 3E8, and 7D3; the humanized version of muMAb 4D5 (hu4D5); or the isotype-matched irrelevant

control MAb 1766. Treatment was for 3 days at a MAb concentration of 10 $\mu$ g/ml. The data are pooled from 2-9 separate experiments and are represented as mean fold increase (+/-s.e.) in annexin V binding over control cells. The response of the BT474 breast tumor cells to MAbs 7C2 and 4D5 is as described for Fig. 5 (9-fold and 2.5-fold above control, respectively). Induction of apoptosis in the SKBR3 breast tumor cell line, which expresses high levels of ErbB2 similar to the BT474 cells, also occurs after treatment with MAb 7C2 (and to a smaller degree, MAb 4D5). In addition, MAb 7F3 induces apoptosis in both the BT474 and SKBR3 cell lines. The MCF7 breast tumor line, which expresses normal ErbB2 levels, and the HMEC's showed no change in annexin V binding after treatment with the anti-ErbB2 Mabs. These results suggest that overexpression of ErbB2 is required for responsiveness to the anti-ErbB2 MAbs. In Fig. 8E, a non-small cell lung carcinoma line overexpressing ErbB2, Calu 3, was tested for induction of apoptosis by anti-ErbB2 MAbs. Treatment with 7C2 or 7F3 resulted in enhanced binding of annexin V.

Figs. 9A-I show the effects of MAbs 7C2 and 4D5 on cell cycle progression and cell death. Untreated BT474 cells are largely annexin V-negative and PI-negative (Fig. 9A, quadrant 3), and show a normal cell cycle DNA histogram (Figs. 9B &C). Cells treated with 10 $\mu$ g/ml MAb 4D5 show some increase in uptake of PI and annexin V-FITC binding (Fig. 9D, quadrant 2). The most pronounced effect is on cell cycle progression, where MAb 4D5 almost completely reduces the percent of cells in S phase (Figs. 9E &F). MAb 7C2 induces a significant amount of cell death in BT474, as measured by PI uptake and annexin V-FITC binding (Fig. 9G, quadrant 2). Cell cycle analysis shows the presence of a sub-G<sub>0</sub>/G<sub>1</sub>, or hypodiploid population (Fig. 9I), characteristic of apoptotic cells, with the cells displaying high levels of annexin V binding (Fig. 9H, quadrant 1).

Figs. 10A-F are the results from curve-fitting analyses of the DNA histograms of Figs. 9A-I and show little change in the percent of cells in S-phase (52%) after MAb 7C2 treatment compared to control cells (61% S-phase cells), but a dramatic reduction in the number of cells in S-phase (to 6%) in response to MAb 4D5 (Figs. 10C, A and B, respectively). Analyses of the apoptotic population of cells (annexin V/PI positive cells from quadrant 2, 9A, D and G) reveal no difference in the percent S-phase cells compared to the total cell population (Fig. 10D control=55%; Fig. 10E MAb 4D5=7%; Fig. 10F MAb 7C2=56%). Furthermore, the G<sub>0</sub>/G<sub>1</sub> and G<sub>2</sub>/M phases show no change (compare Figs. 10A and D, B and E, C and F), indicating that cells are exiting the cell cycle at all phases and that MAb-induced apoptotic cell death is not cell cycle specific.

Figs. 11A & B show MAb 7C2-induced apoptosis is enhanced by growth arrest. In addition to the data from cell cycle studies, it was observed, from video time-lapse recording, that a proportion of MAb 7C2-treated cells continue to proliferate while others undergo apoptosis. Therefore, experiments were performed to determine if inhibition of cell growth would enhance the pro-apoptotic activity of MAb 7C2. BT474 cells were serum-deprived for 3 days to induce 5 growth arrest, then treated with 10 $\mu$ g/ml MAb 7C2 or 4D5 for 3 days and analyzed for viability (annexin V-FITC binding and PI uptake) as well as cell cycle effects. Serum-deprivation (by incubation in media supplemented with 0.1% FBS) effectively reduces proliferation, as seen by a decrease in the percent of S-phase cells from 33% (in 10% FBS) to 10% (Fig. 11A). The potent anti-proliferative activity of MAb 4D5 is not further enhanced by prior growth arrest. The 10 proportion of cells in S-phase, with and without serum-deprivation, in MAb 7C2-treated cells was similar to controls. Fig. 11B shows that serum-starvation does not adversely affect cell viability of untreated cells. However, viability is reduced to 55% in BT474 cells treated with 10 $\mu$ g/ml MAb 4D5 after a period of serum-deprivation. Moreover, treatment of growth-arrested cells with 10 $\mu$ g/ml MAb 7C2 almost completely eradicates the entire culture, in that the percent of annexin 15 V-negative and PI-negative cells is reduced to 10%.

Fig. 12 depicts with underlining the amino acid sequence of Domain 1 of ErbB2 (SEQ ID NO:1). Bold amino acids indicate the location of the epitope recognized by MAbs 7C2 and 7F3 as determined by deletion mapping, *i.e.* the "7C2/7F3 epitope" (SEQ ID NO:2).

Fig. 13 shows epitope-mapping of the extracellular domain of ErbB2 as determined by 20 truncation mutant analysis and site-directed mutagenesis (Nakamura *et al.* *J. of Virology* 67(10):6179-6191 (Oct 1993); Renz *et al.* *J. Cell Biol.* 125(6):1395-1406 (Jun 1994)). Pro-apoptotic MAbs 7C2 and 7F3 bind an epitope at the N-terminus of the receptor, whereas anti-proliferative MAbs 4D5 and 3H4 bind adjacent to the transmembrane domain. The various 25 ErbB2-ECD truncations or point mutations were prepared from cDNA using polymerase chain reaction technology. The ErbB2 mutants were expressed as gD fusion proteins in a mammalian expression plasmid. This expression plasmid uses the cytomegalovirus promoter/enhancer with SV40 termination and polyadenylation signals located downstream of the inserted cDNA. Plasmid DNA was transfected into 293S cells. One day following transfection, the cells were metabolically labeled overnight in methionine and cysteine-free, low glucose DMEM containing 30 1% dialyzed fetal bovine serum and 25  $\mu$ Ci each of  $^{35}$ S methionine and  $^{35}$ S cysteine. Supernatants were harvested either the ErbB2 MAbs or control antibodies were added to the

supernatant and incubated 2-4 hours at 4°C. The complexes were precipitated, applied to a 10-20% Tricine SDS gradient gel and electrophoresed at 100 V. The gel was electroblotted onto a membrane and analyzed by autoradiography.

Figs. 14A-E show that the effects of anti-ErbB2 MAbs are epitope-specific. To determine if the anti-proliferative or pro-apoptotic effects of anti-ErbB2 MAbs are related to epitope specificity, BT474 cells were treated with 4 different MAbs for 3 days and stained with Hoechst 33342 for cell cycle analysis. The MAbs were: 7C2 and 7F3, which bind amino acids 22-53 (SEQ ID NO:2) on the ErbB2 extracellular domain (Figs. 14B and C, respectively); 4D5, which binds residues 561-625 (SEQ ID NO:4) (Fig. 14D); and 3H4, which binds amino acids 541-599 (SEQ ID NO:3) (Fig. 14E). Both 7C2 and 7F3 induce apoptosis (to 60.5% and 53.4%, respectively, of the cell population), but did not decrease the proportion of S-phase cells (64.9% and 58.7%, respectively) compared to untreated cells (52.5%; Fig. 14A). In contrast, MAbs 4D5 and 3H4, which bind adjacent to the ErbB2 transmembrane region, show potent anti-proliferative activity (%S=5.4 and 10.5, respectively, control S=52.5%), but are not as effective as 7C2 or 7F3 in promoting apoptotic cell death (% apoptosis for 4D5=41.9, for 3H4=26.3, controls=15.8%).

### Detailed Description of the Preferred Embodiments

#### I. Definitions

Unless indicated otherwise, the term "ErbB2" when used herein refers to human ErbB2 protein and "erbB2" refers to human erbB2 gene. The human erbB2 gene and ErbB2 protein are described in Semba *et al.*, *PNAS (USA)* 82:6497-6501 (1985) and Yamamoto *et al.* *Nature* 319:230-234 (1986) (Genebank accession number X03363), for example. ErbB2 comprises four domains (Domains 1-4). "Domain 1" at the amino terminus of the extracellular domain of ErbB2 is shown in Fig. 12 herein. See Plowman *et al.* *Proc. Natl. Acad. Sci USA* 90:1746-1750 (1993).

The "epitope 7C2/7F3" is the region at the N terminus of the extracellular domain of ErbB2 to which the 7C2 and/or 7F3 antibodies (each deposited with the ATCC, see below) bind. To screen for antibodies which bind to the 7C2/7F3 epitope, a routine cross-blocking assay such as that described in *Antibodies, A Laboratory Manual*, Cold Spring Harbor Laboratory, Ed Harlow and David Lane (1988), can be performed. Alternatively, epitope mapping can be performed (see Example 2 below) to establish whether the antibody binds to the 7C2/7F3 epitope on ErbB2 (*i.e.* any one or more of residues in the region from about residue 22 to about residue 53 of ErbB2 (SEQ ID NO:2)).

The "epitope 4D5" is the region in the extracellular domain of ErbB2 to which the antibody 4D5 (ATCC CRL 10463) binds. This epitope is close to the transmembrane region of ErbB2. To screen for antibodies which bind to the 4D5 epitope, a routine cross-blocking assay such as that described in *Antibodies, A Laboratory Manual*, Cold Spring Harbor Laboratory, Ed Harlow and David Lane (1988), can be performed. Alternatively, epitope mapping can be performed  
5 (see Example 2 below) to assess whether the antibody binds to the 4D5 epitope of ErbB2 (i.e. any one or more residues in the region from about residue 561 to about residue 625, inclusive (SEQ ID NO:4)).

The term "induces cell death" refers to the ability of the antibody to make a viable cell become nonviable. The "cell" here is one which expresses the ErbB2 receptor, especially where  
10 the cell overexpresses the ErbB2 receptor. A cell which "overexpresses" ErbB2 has significantly higher than normal ErbB2 levels compared to a noncancerous cell of the same tissue type. Preferably, the cell is a cancer cell, e.g. a breast, ovarian, stomach, endometrial, salivary gland, lung, kidney, colon, thyroid, pancreatic or bladder cell. *In vitro*, the cell may be a SKBR3, BT474, Calu 3, MDA-MB-453, MDA-MB-361 or SKOV3 cell. Cell death *in vitro* may be determined in the  
15 absence of complement and immune effector cells to distinguish cell death induced by antibody dependent cellular cytotoxicity (ADCC) or complement dependent cytotoxicity (CDC). Thus, the assay for cell death may be performed using heat inactivated serum (i.e. in the absence of complement) and in the absence of immune effector cells. To determine whether the antibody is able to induce cell death, loss of membrane integrity as evaluated by uptake of propidium  
20 iodide (PI) (see Example 2 below), trypan blue (see Moore et al. *Cytotechnology* 17:1-11 (1995)) or 7AAD (see Example 1 below) can be assessed relative to untreated cells. Preferred cell death-inducing antibodies are those which induce PI uptake in the "PI uptake assay in BT474 cells" (see below)

The phrase "induces apoptosis" refers to the ability of the antibody to induce programmed  
25 cell death as determined by binding of annexin V, fragmentation of DNA, cell shrinkage, dilation of endoplasmatic reticulum, cell fragmentation, and/or formation of membrane vesicles (called apoptotic bodies). See Figs. 1A & B herein. The cell is one which overexpresses the ErbB2 receptor. Preferably the "cell" is a tumor cell, e.g. a breast, ovarian, stomach, endometrial, salivary gland, lung, kidney, colon, thyroid, pancreatic or bladder cell. *In vitro*, the cell may be  
30 a SKBR3, BT474, Calu 3 cell, MDA-MB-453, MDA-MB-361 or SKOV3 cell. Various methods are available for evaluating the cellular events associated with apoptosis. For example, phosphatidyl

serine (PS) translocation can be measured by annexin binding (see Example 2 below); DNA fragmentation can be evaluated through DNA laddering as disclosed in Example 2 herein; and nuclear/chromatin condensation along with DNA fragmentation can be evaluated by any increase in hypodiploid cells. Preferably, the antibody which induces apoptosis is one which results in about 2 to 50 fold, preferably about 5 to 50 fold, and most preferably about 10 to 50 fold, 5 induction of annexin binding relative to untreated cell in an "annexin binding assay using BT474 cells" (see below).

Sometimes the pro-apoptotic antibody will be one which blocks HRG binding/activation of the ErbB2/ErbB3 complex (e.g. 7F3 antibody). In other situations, the antibody is one which does not significantly block activation of the ErbB2/ErbB3 receptor complex by HRG (e.g. 7C2). 10 Further, the antibody may be one like 7C2 which, while inducing apoptosis, does not induce a large reduction in the percent of cells in S phase (e.g. one which only induces about 0-10% reduction in the percent of these cells relative to control as determined in Fig. 10).

The antibody of interest may be one like 7C2 which binds specifically to human ErbB2 and does not significantly cross-react with other proteins such as those encoded by the erbB1, 15 erbB3 and/or erbB4 genes. Sometimes, the antibody may not significantly cross-react with the rat *neu* protein, e.g., as described in Schechter *et al.* *Nature* 312:513 (1984) and Drebin *et al.*, *Nature* 312:545-548 (1984). In such embodiments, the extent of binding of the antibody to these proteins (e.g., cell surface binding to endogenous receptor) will be less than about 10% as determined by fluorescence activated cell sorting (FACS) analysis or radioimmunoprecipitation 20 (RIA).

"Heregulin" (HRG) when used herein refers to a polypeptide which activates the ErbB2-ErbB3 and ErbB2-ErbB4 protein complexes (*i.e.* induces phosphorylation of tyrosine residues in the complex upon binding thereto). Various heregulin polypeptides encompassed by this term are disclosed in Holmes *et al.*, *Science*, 256:1205-1210 (1992); WO 92/20798; Wen *et al.*, *Mol. 25 Cell. Biol.*, 14(3):1909-1919 (1994); and Marchionni *et al.*, *Nature*, 362:312-318 (1993), for example. The term includes biologically active fragments and/or variants of a naturally occurring HRG polypeptide, such as an EGF-like domain fragment thereof (e.g. HRG $\beta$ 1<sub>177-244</sub>).

The "ErbB2-ErbB3 protein complex" and "ErbB2-ErbB4 protein complex" are noncovalently associated oligomers of the ErbB2 receptor and the ErbB3 receptor or ErbB4 receptor, respectively. The complexes form when a cell expressing both of these receptors is exposed to HRG and can be isolated by immunoprecipitation and analyzed by SDS-PAGE as 30

described in Sliwkowski et al., *J. Biol. Chem.*, 269(20):14661-14665 (1994).

"Antibodies" (Abs) and "immunoglobulins" (Igs) are glycoproteins having the same structural characteristics. While antibodies exhibit binding specificity to a specific antigen, immunoglobulins include both antibodies and other antibody-like molecules which lack antigen specificity. Polypeptides of the latter kind are, for example, produced at low levels by the lymph

5 system and at increased levels by myelomas.

"Native antibodies" and "native immunoglobulins" are usually heterotetrameric glycoproteins of about 150,000 daltons, composed of two identical light (L) chains and two identical heavy (H) chains. Each light chain is linked to a heavy chain by one covalent disulfide bond, while the number of disulfide linkages varies among the heavy chains of different

10 immunoglobulin isotypes. Each heavy and light chain also has regularly spaced intrachain disulfide bridges. Each heavy chain has at one end a variable domain ( $V_H$ ) followed by a number of constant domains. Each light chain has a variable domain at one end ( $V_L$ ) and a constant domain at its other end; the constant domain of the light chain is aligned with the first constant domain of the heavy chain, and the light- chain variable domain is aligned with the variable domain of the heavy chain. Particular amino acid residues are believed to form an interface

15 between the light- and heavy-chain variable domains.

The term "variable" refers to the fact that certain portions of the variable domains differ extensively in sequence among antibodies and are used in the binding and specificity of each particular antibody for its particular antigen. However, the variability is not evenly distributed

20 throughout the variable domains of antibodies. It is concentrated in three segments called complementarity-determining regions (CDRs) or hypervariable regions both in the light-chain and the heavy-chain variable domains. The more highly conserved portions of variable domains are called the framework (FR). The variable domains of native heavy and light chains each comprise

25 four FR regions, largely adopting a  $\beta$ -sheet configuration, connected by three CDRs, which form loops connecting, and in some cases forming part of, the  $\beta$ -sheet structure. The CDRs in each chain are held together in close proximity by the FR regions and, with the CDRs from the other chain, contribute to the formation of the antigen-binding site of antibodies (see Kabat et al., *NIH Publ.* No.91-3242, Vol. I, pages 647-669 (1991)). The constant domains are not involved directly

30 in binding an antibody to an antigen, but exhibit various effector functions, such as participation of the antibody in antibody-dependent cellular toxicity.

Papain digestion of antibodies produces two identical antigen- binding fragments, called

"Fab" fragments, each with a single antigen-binding site, and a residual "Fc" fragment, whose name reflects its ability to crystallize readily. Pepsin treatment yields an  $F(ab')_2$  fragment that has two antigen-combining sites and is still capable of cross-linking antigen.

"Fv" is the minimum antibody fragment which contains a complete antigen-recognition and -binding site. This region consists of a dimer of one heavy- and one light-chain variable domain in tight, non-covalent association. It is in this configuration that the three CDRs of each variable domain interact to define an antigen-binding site on the surface of the  $V_H$ - $V_L$  dimer. Collectively, the six CDRs confer antigen-binding specificity to the antibody. However, even a single variable domain (or half of an Fv comprising only three CDRs specific for an antigen) has the ability to recognize and bind antigen, although at a lower affinity than the entire binding site.

The Fab fragment also contains the constant domain of the light chain and the first constant domain (CH1) of the heavy chain. Fab fragments differ from Fab fragments by the addition of a few residues at the carboxy terminus of the heavy chain CH1 domain including one or more cysteines from the antibody hinge region. Fab'-SH is the designation herein for Fab' in which the cysteine residue(s) of the constant domains bear a free thiol group.  $F(ab')_2$  antibody fragments originally were produced as pairs of Fab' fragments which have hinge cysteines between them. Other chemical couplings of antibody fragments are also known.

The "light chains" of antibodies (immunoglobulins) from any vertebrate species can be assigned to one of two clearly distinct types, called kappa ( $\kappa$ ) and lambda ( $\lambda$ ), based on the amino acid sequences of their constant domains.

Depending on the amino acid sequence of the constant domain of their heavy chains, immunoglobulins can be assigned to different classes. There are five major classes of immunoglobulins: IgA, IgD, IgE, IgG, and IgM, and several of these may be further divided into subclasses (isotypes), e.g., IgG1, IgG2, IgG3, IgG4, IgA, and IgA2. The heavy-chain constant domains that correspond to the different classes of immunoglobulins are called  $\alpha$ ,  $\delta$ ,  $\epsilon$ ,  $\gamma$ , and  $\mu$ , respectively. The subunit structures and three-dimensional configurations of different classes of immunoglobulins are well known.

The term "antibody" is used in the broadest sense and specifically covers intact monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g. bispecific antibodies) formed from at least two intact antibodies, and antibody fragments so long as they exhibit the desired biological activity.

"Antibody fragments" comprise a portion of an intact antibody, preferably the antigen

binding or variable region of the intact antibody. Examples of antibody fragments include Fab, Fab', F(ab')<sub>2</sub>, and Fv fragments; diabodies; linear antibodies (Zapata et al. *Protein Eng.* 8(10):1057-1062 (1995)); single-chain antibody molecules; and multispecific antibodies formed from antibody fragments.

The term "monoclonal antibody" as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site. Furthermore, in contrast to conventional (polyclonal) antibody preparations which typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen. In addition to their specificity, the monoclonal antibodies are advantageous in that they are synthesized by the hybridoma culture, uncontaminated by other immunoglobulins. The modifier "monoclonal" indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method. For example, the monoclonal antibodies to be used in accordance with the present invention may be made by the hybridoma method first described by Kohler et al., *Nature*, 256:495 (1975), or may be made by recombinant DNA methods (see, e.g., U.S. Patent No. 4,816,567). The "monoclonal antibodies" may also be isolated from phage antibody libraries using the techniques described in Clackson et al., *Nature*, 352:624-628 (1991) and Marks et al., *J. Mol. Biol.*, 222:581-597 (1991), for example.

The monoclonal antibodies herein specifically include "chimeric" antibodies (immunoglobulins) in which a portion of the heavy and/or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired biological activity (U.S. Patent No. 4,816,567; Morrison et al., *Proc. Natl. Acad. Sci. USA*, 81:6851-6855 (1984)).

"Humanized" forms of non-human (e.g., murine) antibodies are chimeric immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab')<sub>2</sub> or other antigen-binding subsequences of antibodies) which contain minimal sequence derived

from non-human immunoglobulin. For the most part, humanized antibodies are human immunoglobulins (recipient antibody) in which residues from a complementarity-determining region (CDR) of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity, and capacity. In some instances, Fv framework region (FR) residues of the human immunoglobulin are  
5 replaced by corresponding non-human residues. Furthermore, humanized antibodies may comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. These modifications are made to further refine and maximize antibody performance. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions  
10 correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin. For further details, see Jones *et al.*, *Nature*, 321:522-525 (1986); Reichmann  
15 *et al.*, *Nature*, 332:323-329 (1988); and Presta, *Curr. Op. Struct. Biol.*, 2:593-596 (1992). The humanized antibody includes a PRIMATIZED™ antibody wherein the antigen-binding region of the antibody is derived from an antibody produced by immunizing macaque monkeys with the antigen of interest.

"Single-chain Fv" or "sFv" antibody fragments comprise the  $V_H$  and  $V_L$  domains of antibody, wherein these domains are present in a single polypeptide chain. Preferably, the Fv polypeptide further comprises a polypeptide linker between the  $V_H$  and  $V_L$  domains which enables the sFv to form the desired structure for antigen binding. For a review of sFv see Pluckthun in *The Pharmacology of Monoclonal Antibodies*, vol. 113, Rosenberg and Moore eds., Springer-Verlag, New York, pp. 269-315 (1994).

The term "diabodies" refers to small antibody fragments with two antigen-binding sites, which fragments comprise a heavy-chain variable domain ( $V_H$ ) connected to a light-chain variable domain ( $V_L$ ) in the same polypeptide chain ( $V_H - V_L$ ). By using a linker that is too short to allow pairing between the two domains on the same chain, the domains are forced to pair with the complementary domains of another chain and create two antigen-binding sites. Diabodies are described more fully in, for example, EP 404,097; WO 93/11161; and Hollinger *et al.*, *Proc. Natl. Acad. Sci. USA*, 90:6444-6448 (1993).

An "isolated" antibody is one which has been identified and separated and/or recovered

from a component of its natural environment. Contaminant components of its natural environment are materials which would interfere with diagnostic or therapeutic uses for the antibody, and may include enzymes, hormones, and other proteinaceous or nonproteinaceous solutes. In preferred embodiments, the antibody will be purified (1) to greater than 95% by weight of antibody as determined by the Lowry method, and most preferably more than 99% by weight, (2) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence by use of a spinning cup sequenator, or (3) to homogeneity by SDS-PAGE under reducing or nonreducing conditions using Coomassie blue or, preferably, silver stain. Isolated antibody includes the antibody *in situ* within recombinant cells since at least one component of the antibody's natural environment will not be present. Ordinarily, however, isolated antibody will be prepared by at least one purification step.

As used herein, the term "salvage receptor binding epitope" refers to an epitope of the Fc region of an IgG molecule (e.g., IgG<sub>1</sub>, IgG<sub>2</sub>, IgG<sub>3</sub>, or IgG<sub>4</sub>) that is responsible for increasing the *in vivo* serum half-life of the IgG molecule.

"Treatment" refers to both therapeutic treatment and prophylactic or preventative measures. Those in need of treatment include those already with the disorder as well as those in which the disorder is to be prevented.

"Mammal" for purposes of treatment refers to any animal classified as a mammal, including humans, domestic and farm animals, and zoo, sports, or pet animals, such as dogs, horses, cats, cows, etc. Preferably, the mammal is human.

A "disorder" is any condition that would benefit from treatment with the anti-ErbB2 antibody. This includes chronic and acute disorders or diseases including those pathological conditions which predispose the mammal to the disorder in question. Non-limiting examples of disorders to be treated herein include benign and malignant tumors; leukemias and lymphoid malignancies; neuronal, glial, astrocytal, hypothalamic and other glandular, macrophagal, epithelial, stromal and blastocoelic disorders; and inflammatory, angiogenic and immunologic disorders.

The terms "cancer" and "cancerous" refer to or describe the physiological condition in mammals that is typically characterized by unregulated cell growth. Examples of cancer include but are not limited to, carcinoma, lymphoma, blastoma, sarcoma, and leukemia. More particular examples of such cancers include squamous cell cancer, small-cell lung cancer, non-small cell lung cancer, gastrointestinal cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian

cancer, liver cancer, bladder cancer, hepatoma, breast cancer, colon cancer, colorectal cancer, endometrial carcinoma, salivary gland carcinoma, kidney cancer, liver cancer, prostate cancer, vulval cancer, thyroid cancer, hepatic carcinoma and various types of head and neck cancer.

The term "cytotoxic agent" as used herein refers to a substance that inhibits or prevents the function of cells and/or causes destruction of cells. The term is intended to include 5 radioactive isotopes (e.g. I<sup>131</sup>, I<sup>125</sup>, Y<sup>90</sup> and Re<sup>186</sup>), chemotherapeutic agents, and toxins such as enzymatically active toxins of bacterial, fungal, plant or animal origin, or fragments thereof.

A "chemotherapeutic agent" is a chemical compound useful in the treatment of cancer. Examples of chemotherapeutic agents include Adriamycin, Doxorubicin, 5-Fluorouracil, Cytosine arabinoside ("Ara-C"), Cyclophosphamide, Thiotepa, Busulfan, Cytoxin, Taxol, Toxotere, 10 Methotrexate, Cisplatin, Melphalan, Vinblastine, Bleomycin, Etoposide, Ifosfamide, Mitomycin C, Mitoxantrone, Vincreistine, Vinorelbine, Carboplatin, Teniposide, Daunomycin, Carminomycin, Aminopterin, Dactinomycin, Mitomycins, Esperamicins (see U.S. Pat. No. 4,675,187), Melphalan and other related nitrogen mustards. Also included in this definition are hormonal agents that act to regulate or inhibit hormone action on tumors such as tamoxifen and onapristone.

15 A "growth inhibitory agent" when used herein refers to a compound or composition which inhibits growth of a cell, especially an ErbB2-overexpressing cancer cell either *in vitro* or *in vivo*. Thus, the growth inhibitory agent is one which significantly reduces the percentage of ErbB2 overexpressing cells in S phase. Examples of growth inhibitory agents include agents that block cell cycle progression (at a place other than S phase), such as agents that induce G1 arrest and M-phase arrest. Classical M-phase blockers include the vincas (vincristine and vinblastine), taxol, and topo II inhibitors such as doxorubicin, daunorubicin, etoposide, and bleomycin. Those agents that arrest G1 also spill over into S-phase arrest, for example, DNA alkylating agents such as tamoxifen, prednisone, dacarbazine, mechlorethamine, cisplatin, methotrexate, 5-fluorouracil, and ara-C. Further information can be found in *The Molecular Basis of Cancer*, 20 Mendelsohn and Israel, eds., Chapter 1, entitled "Cell cycle regulation, oncogens, and antineoplastic drugs" by Murakami *et al.* (WB Saunders: Philadelphia, 1995), especially p. 13. The 4D5 antibody (and functional equivalents thereof) can also be employed for this purpose.

The term "cytokine" is a generic term for proteins released by one cell population which act on another cell as intercellular mediators. Examples of such cytokines are lymphokines, 30 monokines, and traditional polypeptide hormones. Included among the cytokines are growth hormone such as human growth hormone, N-methionyl human growth hormone, and bovine

growth hormone; parathyroid hormone; thyroxine; insulin; proinsulin; relaxin; prorelaxin; glycoprotein hormones such as follicle stimulating hormone (FSH), thyroid stimulating hormone (TSH), and luteinizing hormone (LH); hepatic growth factor; fibroblast growth factor; prolactin; placental lactogen; tumor necrosis factor- $\alpha$  and - $\beta$ ; mullerian-inhibiting substance; mouse gonadotropin-associated peptide; inhibin; activin; vascular endothelial growth factor; integrin; 5 thrombopoietin (TPO); nerve growth factors such as NGF- $\beta$ ; platelet-growth factor; transforming growth factors (TGFs) such as TGF- $\alpha$  and TGF- $\beta$ ; insulin-like growth factor-I and -II; erythropoietin (EPO); osteoinductive factors; interferons such as interferon- $\alpha$ , - $\beta$ , and - $\gamma$ ; colony 10 stimulating factors (CSFs) such as macrophage-CSF (M-CSF); granulocyte-macrophage-CSF (GM-CSF); and granulocyte-CSF (G-CSF); interleukins (ILs) such as IL-1, IL-1 $\alpha$ , IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-11, IL-12; a tumor necrosis factor such as TNF- $\alpha$  or TNF- $\beta$ ; and 15 other polypeptide factors including LIF and kit ligand (KL). As used herein, the term cytokine includes proteins from natural sources or from recombinant cell culture and biologically active equivalents of the native sequence cytokines.

The term "prodrug" as used in this application refers to a precursor or derivative form 20 of a pharmaceutically active substance that is less cytotoxic to tumor cells compared to the parent drug and is capable of being enzymatically activated or converted into the more active parent form. See, e.g., Wilman, "Prodrugs in Cancer Chemotherapy" *Biochemical Society Transactions*, 14, pp. 375-382, 615th Meeting Belfast (1986) and Stella et al., "Prodrugs: A Chemical Approach to Targeted Drug Delivery," *Directed Drug Delivery*, Borchardt et al., (ed.), pp. 247-267, Humana Press (1985). The prodrugs of this invention include, but are not limited to, phosphate-containing prodrugs, thiophosphate-containing prodrugs, sulfate-containing prodrugs, peptide-containing prodrugs, D-amino acid-modified prodrugs, glycosylated prodrugs,  $\beta$ -lactam-containing prodrugs, optionally substituted phenoxyacetamide-containing prodrugs or 25 optionally substituted phenylacetamide-containing prodrugs, 5-fluorocytosine and other 5-fluorouridine prodrugs which can be converted into the more active cytotoxic free drug. Examples of cytotoxic drugs that can be derivatized into a prodrug form for use in this invention include, but are not limited to, those chemotherapeutic agents described above.

The word "label" when used herein refers to a detectable compound or composition 30 which is conjugated directly or indirectly to the antibody so as to generate a "labelled" antibody. The label may be detectable by itself (e.g. radioisotope labels or fluorescent labels) or, in the case of an enzymatic label, may catalyze chemical alteration of a substrate compound or

composition which is detectable.

By "solid phase" is meant a non-aqueous matrix to which the antibody of the present invention can adhere. Examples of solid phases encompassed herein include those formed partially or entirely of glass (e.g., controlled pore glass), polysaccharides (e.g., agarose), polyacrylamides, polystyrene, polyvinyl alcohol and silicones. In certain embodiments, depending  
5 on the context, the solid phase can comprise the well of an assay plate; in others it is a purification column (e.g., an affinity chromatography column). This term also includes a discontinuous solid phase of discrete particles, such as those described in U.S. Patent No. 4,275,149.

A "liposome" is a small vesicle composed of various types of lipids, phospholipids and/or surfactant which is useful for delivery of a drug (such as the anti-ErbB2 antibodies disclosed  
10 herein and, optionally, a chemotherapeutic agent) to a mammal. The components of the liposome are commonly arranged in a bilayer formation, similar to the lipid arrangement of biological membranes.

An "isolated" nucleic acid molecule is a nucleic acid molecule that is identified and separated from at least one contaminant nucleic acid molecule with which it is ordinarily associated in the natural source of the antibody nucleic acid. An isolated nucleic acid molecule is other than in the form or setting in which it is found in nature. Isolated nucleic acid molecules therefore are distinguished from the nucleic acid molecule as it exists in natural cells. However,  
15 an isolated nucleic acid molecule includes a nucleic acid molecule contained in cells that ordinarily express the antibody where, for example, the nucleic acid molecule is in a chromosomal location different from that of natural cells.  
20

The expression "control sequences" refers to DNA sequences necessary for the expression of an operably linked coding sequence in a particular host organism. The control sequences that are suitable for prokaryotes, for example, include a promoter, optionally an  
25 operator sequence, and a ribosome binding site. Eukaryotic cells are known to utilize promoters, polyadenylation signals, and enhancers.

Nucleic acid is "operably linked" when it is placed into a functional relationship with another nucleic acid sequence. For example, DNA for a presequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the  
30 secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a

coding sequence if it is positioned so as to facilitate translation. Preferably, "operably linked" means that the DNA sequences being linked are contiguous, and, in the case of a secretory leader, contiguous and in reading phase. However, enhancers do not have to be contiguous. Linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, the synthetic oligonucleotide adaptors or linkers are used in accordance with conventional practice.

5 As used herein, the expressions "cell," "cell line," and "cell culture" are used interchangeably and all such designations include progeny. Thus, the words "transformants" and "transformed cells" include the primary subject cell and cultures derived therefrom without regard for the number of transfers. It is also understood that all progeny may not be precisely identical in DNA content, due to deliberate or inadvertent mutations. Mutant progeny that have the same 10 function or biological activity as screened for in the originally transformed cell are included. Where distinct designations are intended, it will be clear from the context.

## II. Modes for Carrying out the Invention

### A. Antibody Preparation

15 A description follows as to exemplary techniques for the production of the claimed antibodies. The ErbB2 antigen to be used for production of antibodies may be, e.g., a soluble form of the extracellular domain of ErbB2; a peptide such as a Domain 1 peptide or a portion thereof (e.g. comprising the 7C2 or 7F3 epitope). Alternatively, cells expressing ErbB2 at their 20 cell surface (e.g. NIH-3T3 cells transformed to overexpress ErbB2, see Examples 1 & 2 below; or a carcinoma cell line such as SKBR3 cells, see Stancovski et al. PNAS (USA) 88:8691-8695 (1991)) can be used to generate antibodies. Other forms of ErbB2 useful for generating antibodies will be apparent to those skilled in the art.

#### (i) Polyclonal antibodies

25 Polyclonal antibodies are preferably raised in animals by multiple subcutaneous (sc) or intraperitoneal (ip) injections of the relevant antigen and an adjuvant. It may be useful to conjugate the relevant antigen to a protein that is immunogenic in the species to be immunized, e.g., keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, or soybean trypsin inhibitor using a bifunctional or derivatizing agent, for example, maleimidobenzoyl sulfosuccinimide ester (conjugation through cysteine residues), N-hydroxysuccinimide (through 30 lysine residues), glutaraldehyde, succinic anhydride,  $\text{SOCl}_2$ , or  $\text{R}^1\text{N}=\text{C}=\text{NR}$ , where R and  $\text{R}^1$  are different alkyl groups.

Animals are immunized against the antigen, immunogenic conjugates, or derivatives by combining, e.g., 100 µg or 5 µg of the protein or conjugate (for rabbits or mice, respectively) with 3 volumes of Freund's complete adjuvant and injecting the solution intradermally at multiple sites. One month later the animals are boosted with 1/5 to 1/10 the original amount of peptide or conjugate in Freund's complete adjuvant by subcutaneous injection at multiple sites. Seven to 5 14 days later the animals are bled and the serum is assayed for antibody titer. Animals are boosted until the titer plateaus. Preferably, the animal is boosted with the conjugate of the same antigen, but conjugated to a different protein and/or through a different cross-linking reagent. Conjugates also can be made in recombinant cell culture as protein fusions. Also, aggregating agents such as alum are suitably used to enhance the immune response.

10                   (ii)     *Monoclonal antibodies*

Monoclonal antibodies are obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Thus, the modifier "monoclonal" indicates the character of the antibody as not being a mixture of discrete 15 antibodies.

For example, the monoclonal antibodies may be made using the hybridoma method first described by Kohler *et al.*, *Nature*, 256:495 (1975), or may be made by recombinant DNA methods (U.S. Patent No. 4,816,567).

In the hybridoma method, a mouse or other appropriate host animal, such as a hamster, 20 is immunized as hereinabove described to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the protein used for immunization. Alternatively, lymphocytes may be immunized *in vitro*. Lymphocytes then are fused with myeloma cells using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell (Goding, *Monoclonal Antibodies: Principles and Practice*, pp.59-103 (Academic Press, 1986)).

25                   The hybridoma cells thus prepared are seeded and grown in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, parental myeloma cells. For example, if the parental myeloma cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine (HAT medium), which 30 substances prevent the growth of HGPRT-deficient cells.

Preferred myeloma cells are those that fuse efficiently, support stable high-level

production of antibody by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium. Among these, preferred myeloma cell lines are murine myeloma lines, such as those derived from MOPC-21 and MPC-11 mouse tumors available from the Salk Institute Cell Distribution Center, San Diego, California USA, and SP-2 or X63-Ag8-653 cells available from the American Type Culture Collection, Rockville, Maryland USA. Human myeloma  
5 and mouse-human heteromyeloma cell lines also have been described for the production of human monoclonal antibodies (Kozbor, *J. Immunol.*, 133:3001 (1984); Brodeur et al., *Monoclonal Antibody Production Techniques and Applications*, pp. 51-63 (Marcel Dekker, Inc., New York, 1987)).

Culture medium in which hybridoma cells are growing is assayed for production of  
10 monoclonal antibodies directed against the antigen. Preferably, the binding specificity of monoclonal antibodies produced by hybridoma cells is determined by immunoprecipitation or by an *in vitro* binding assay, such as radioimmunoassay (RIA) or enzyme-linked immunoabsorbent assay (ELISA).

The binding affinity of the monoclonal antibody can, for example, be determined by the  
15 Scatchard analysis of Munson et al., *Anal. Biochem.*, 107:220 (1980).

After hybridoma cells are identified that produce antibodies of the desired specificity, affinity, and/or activity, the clones may be subcloned by limiting dilution procedures and grown by standard methods (Goding, *Monoclonal Antibodies: Principles and Practice*, pp.59-103 (Academic Press, 1986)). Suitable culture media for this purpose include, for example, D-MEM  
20 or RPMI-1640 medium. In addition, the hybridoma cells may be grown *in vivo* as ascites tumors in an animal.

The monoclonal antibodies secreted by the subclones are suitably separated from the culture medium, ascites fluid, or serum by conventional immunoglobulin purification procedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis,  
25 dialysis, or affinity chromatography.

DNA encoding the monoclonal antibodies is readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies). The hybridoma cells serve as a preferred source of such DNA. Once isolated, the DNA may be placed into expression vectors, which are then transfected into host cells such as *E. coli* cells, simian COS  
30 cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce

immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells. Review articles on recombinant expression in bacteria of DNA encoding the antibody include Skerra *et al.*, *Curr. Opinion in Immunol.*, 5:256-262 (1993) and Plückthun, *Immunol. Revs.*, 130:151-188 (1992).

In a further embodiment, antibodies or antibody fragments can be isolated from antibody phage libraries generated using the techniques described in McCafferty *et al.*, *Nature*, 348:552-554 (1990). Clackson *et al.*, *Nature*, 352:624-628 (1991) and Marks *et al.*, *J. Mol. Biol.*, 222:581-597 (1991) describe the isolation of murine and human antibodies, respectively, using phage libraries. Subsequent publications describe the production of high affinity (nM range) human antibodies by chain shuffling (Marks *et al.*, *Bio/Technology*, 10:779-783 (1992)), as well as combinatorial infection and *in vivo* recombination as a strategy for constructing very large phage libraries (Waterhouse *et al.*, *Nuc. Acids. Res.*, 21:2265-2266 (1993)). Thus, these techniques are viable alternatives to traditional monoclonal antibody hybridoma techniques for isolation of monoclonal antibodies.

The DNA also may be modified, for example, by substituting the coding sequence for human heavy- and light-chain constant domains in place of the homologous murine sequences (U.S. Patent No. 4,816,567; Morrison, *et al.*, *Proc. Natl Acad. Sci. USA*, 81:6851 (1984)), or by covalently joining to the immunoglobulin coding sequence all or part of the coding sequence for a non-immunoglobulin polypeptide.

Typically such non-immunoglobulin polypeptides are substituted for the constant domains of an antibody, or they are substituted for the variable domains of one antigen-combining site of an antibody to create a chimeric bivalent antibody comprising one antigen-combining site having specificity for an antigen and another antigen-combining site having specificity for a different antigen.

(iii) *Humanized and human antibodies*

Methods for humanizing non-human antibodies are well known in the art. Preferably, a humanized antibody has one or more amino acid residues introduced into it from a source which is non-human. These non-human amino acid residues are often referred to as "import" residues, which are typically taken from an "import" variable domain. Humanization can be essentially performed following the method of Winter and co-workers (Jones *et al.*, *Nature*, 321:522-525 (1986); Riechmann *et al.*, *Nature*, 332:323-327 (1988); Verhoeyen *et al.*, *Science*, 239:1534-1536 (1988)), by substituting rodent CDRs or CDR sequences for the corresponding sequences

of a human antibody. Accordingly, such "humanized" antibodies are chimeric antibodies (U.S. Patent No. 4,816,567) wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species. In practice, humanized antibodies are typically human antibodies in which some CDR residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies.

5       The choice of human variable domains, both light and heavy, to be used in making the  
humanized antibodies is very important to reduce antigenicity. According to the so-called "best-fit" method, the sequence of the variable domain of a rodent antibody is screened against the  
entire library of known human variable-domain sequences. The human sequence which is  
closest to that of the rodent is then accepted as the human framework (FR) for the humanized  
10 antibody (Sims *et al.*, *J. Immunol.*, 151:2296 (1993); Chothia *et al.*, *J. Mol. Biol.*, 196:901 (1987)).  
Another method uses a particular framework derived from the consensus sequence of all human  
antibodies of a particular subgroup of light or heavy chains. The same framework may be used  
for several different humanized antibodies (Carter *et al.*, *Proc. Natl. Acad. Sci. USA*, 89:4285  
(1992); Presta *et al.*, *J. Immunol.*, 151:2623 (1993)).

15       It is further important that antibodies be humanized with retention of high affinity for the  
antigen and other favorable biological properties. To achieve this goal, according to a preferred  
method, humanized antibodies are prepared by a process of analysis of the parental sequences  
and various conceptual humanized products using three-dimensional models of the parental and  
humanized sequences. Three-dimensional immunoglobulin models are commonly available and  
20 are familiar to those skilled in the art. Computer programs are available which illustrate and  
display probable three-dimensional conformational structures of selected candidate  
immunoglobulin sequences. Inspection of these displays permits analysis of the likely role of the  
residues in the functioning of the candidate immunoglobulin sequence, *i.e.*, the analysis of  
residues that influence the ability of the candidate immunoglobulin to bind its antigen. In this  
way, FR residues can be selected and combined from the recipient and import sequences so  
25 that the desired antibody characteristic, such as increased affinity for the target antigen(s), is  
achieved. In general, the CDR residues are directly and most substantially involved in  
influencing antigen binding.

30       Alternatively, it is now possible to produce transgenic animals (*e.g.*, mice) that are  
capable, upon immunization, of producing a full repertoire of human antibodies in the absence  
of endogenous immunoglobulin production. For example, it has been described that the

homozygous deletion of the antibody heavy-chain joining region ( $J_H$ ) gene in chimeric and germ-line mutant mice results in complete inhibition of endogenous antibody production. Transfer of the human germ-line immunoglobulin gene array in such germ-line mutant mice will result in the production of human antibodies upon antigen challenge. See, e.g., Jakobovits *et al.*, *Proc. Natl. Acad. Sci. USA*, 90:2551 (1993); Jakobovits *et al.*, *Nature*, 362:255-258 (1993); Bruggermann *et al.*, *Year in Immuno.*, 7:33 (1993). Human antibodies can also be derived from phage-display libraries (Hoogenboom *et al.*, *J. Mol. Biol.*, 227:381 (1991); Marks *et al.*, *J. Mol. Biol.*, 222:581-597 (1991)).

(iv) *Antibody fragments*

Various techniques have been developed for the production of antibody fragments.

10 Traditionally, these fragments were derived via proteolytic digestion of intact antibodies (see, e.g., Morimoto et al., *Journal of Biochemical and Biophysical Methods* 24:107-117 (1992) and Brennan et al., *Science*, 229:81 (1985)). However, these fragments can now be produced directly by recombinant host cells. For example, the antibody fragments can be isolated from the antibody phage libraries discussed above. Alternatively, Fab'-SH fragments can be directly recovered from *E. coli* and chemically coupled to form F(ab')<sub>2</sub> fragments (Carter et al., 15 *Bio/Technology* 10:163-167 (1992)). According to another approach, F(ab')<sub>2</sub> fragments can be isolated directly from recombinant host cell culture. Other techniques for the production of antibody fragments will be apparent to the skilled practitioner. In other embodiments, the antibody of choice is a single chain Fv fragment (scFv). See WO 93/16185.

(v) *Bispecific antibodies*

Bispecific antibodies are antibodies that have binding specificities for at least two different epitopes. Exemplary bispecific antibodies may bind to two different epitopes of the ErbB2 protein. For example, one arm may bind an epitope in Domain 1 of ErbB2 such as the 7C2/7F3 epitope, the other may bind a different ErbB2 epitope, e.g. the 4D5 epitope. Other such antibodies may combine an ErbB2 binding site with binding site(s) for EGFR, ErbB3 and/or ErbB4. Alternatively, an anti-ErbB2 arm may be combined with an arm which binds to a triggering molecule on a leukocyte such as a T-cell receptor molecule (e.g. CD2 or CD3), or Fc receptors for IgG (Fc $\gamma$ R), such as Fc $\gamma$ RI (CD64), Fc $\gamma$ RII (CD32) and Fc $\gamma$ RIII (CD16) so as to focus cellular defense mechanisms to the ErbB2-expressing cell. Bispecific antibodies may also be used to localize cytotoxic agents to cells which express ErbB2. These antibodies possess an ErbB2-binding arm and an arm which binds the cytotoxic agent (e.g. saporin, anti-interferon- $\alpha$ ,

vinca alkaloid, ricin A chain, methotrexate or radioactive isotope hapten). Bispecific antibodies can be prepared as full length antibodies or antibody fragments (e.g. F(ab')<sub>2</sub> bispecific antibodies).

Methods for making bispecific antibodies are known in the art. Traditional production of full length bispecific antibodies is based on the coexpression of two immunoglobulin heavy chain-light chain pairs, where the two chains have different specificities (Millstein *et al.*, *Nature*, 305:537-539 (1983)). Because of the random assortment of immunoglobulin heavy and light chains, these hybridomas (quadromas) produce a potential mixture of 10 different antibody molecules, of which only one has the correct bispecific structure. Purification of the correct molecule, which is usually done by affinity chromatography steps, is rather cumbersome, and the product yields are low. Similar procedures are disclosed in WO 93/08829, and in Traunecker *et al.*, *EMBO J.*, 10:3655-3659 (1991).

According to a different approach, antibody variable domains with the desired binding specificities (antibody-antigen combining sites) are fused to immunoglobulin constant domain sequences. The fusion preferably is with an immunoglobulin heavy chain constant domain, comprising at least part of the hinge, CH2, and CH3 regions. It is preferred to have the first heavy-chain constant region (CH1) containing the site necessary for light chain binding, present in at least one of the fusions. DNAs encoding the immunoglobulin heavy chain fusions and, if desired, the immunoglobulin light chain, are inserted into separate expression vectors, and are co-transfected into a suitable host organism. This provides for great flexibility in adjusting the mutual proportions of the three polypeptide fragments in embodiments when unequal ratios of the three polypeptide chains used in the construction provide the optimum yields. It is, however, possible to insert the coding sequences for two or all three polypeptide chains in one expression vector when the expression of at least two polypeptide chains in equal ratios results in high yields or when the ratios are of no particular significance.

In a preferred embodiment of this approach, the bispecific antibodies are composed of a hybrid immunoglobulin heavy chain with a first binding specificity in one arm, and a hybrid immunoglobulin heavy chain-light chain pair (providing a second binding specificity) in the other arm. It was found that this asymmetric structure facilitates the separation of the desired bispecific compound from unwanted immunoglobulin chain combinations, as the presence of an immunoglobulin light chain in only one half of the bispecific molecule provides for a facile way of separation. This approach is disclosed in WO 94/04690. For further details of generating

bispecific antibodies see, for example, Suresh *et al.*, *Methods in Enzymology*, 121:210 (1986).

According to another approach described in W096/27011, the interface between a pair of antibody molecules can be engineered to maximize the percentage of heterodimers which are recovered from recombinant cell culture. The preferred interface comprises at least a part of the C<sub>H</sub>3 domain of an antibody constant domain. In this method, one or more small amino acid side chains from the interface of the first antibody molecule are replaced with larger side chains (e.g. tyrosine or tryptophan). Compensatory "cavities" of identical or similar size to the large side chain(s) are created on the interface of the second antibody molecule by replacing large amino acid side chains with smaller ones (e.g. alanine or threonine). This provides a mechanism for increasing the yield of the heterodimer over other unwanted end-products such as homodimers.

Bispecific antibodies include cross-linked or "heteroconjugate" antibodies. For example, one of the antibodies in the heteroconjugate can be coupled to avidin, the other to biotin. Such antibodies have, for example, been proposed to target immune system cells to unwanted cells (US Patent No. 4,676,980), and for treatment of HIV infection (WO 91/00360, WO 92/200373, and EP 03089). Heteroconjugate antibodies may be made using any convenient cross-linking methods. Suitable cross-linking agents are well known in the art, and are disclosed in US Patent No. 4,676,980, along with a number of cross-linking techniques.

Techniques for generating bispecific antibodies from antibody fragments have also been described in the literature. For example, bispecific antibodies can be prepared using chemical linkage. Brennan *et al.*, *Science*, 229: 81 (1985) describe a procedure wherein intact antibodies are proteolytically cleaved to generate F(ab')<sub>2</sub> fragments. These fragments are reduced in the presence of the dithiol complexing agent sodium arsenite to stabilize vicinal dithiols and prevent intermolecular disulfide formation. The Fab' fragments generated are then converted to thionitrobenzoate (TNB) derivatives. One of the Fab'-TNB derivatives is then reconverted to the Fab'-thiol by reduction with mercaptoethylamine and is mixed with an equimolar amount of the other Fab'-TNB derivative to form the bispecific antibody. The bispecific antibodies produced can be used as agents for the selective immobilization of enzymes.

Recent progress has facilitated the direct recovery of Fab'-SH fragments from *E. coli*, which can be chemically coupled to form bispecific antibodies. Shalaby *et al.*, *J. Exp. Med.*, 175: 217-225 (1992) describe the production of a fully humanized bispecific antibody F(ab')<sub>2</sub> molecule. Each Fab' fragment was separately secreted from *E. coli* and subjected to directed chemical

coupling *in vitro* to form the bispecific antibody. The bispecific antibody thus formed was able to bind to cells overexpressing the ErbB2 receptor and normal human T cells, as well as trigger the lytic activity of human cytotoxic lymphocytes against human breast tumor targets.

Various techniques for making and isolating bispecific antibody fragments directly from recombinant cell culture have also been described. For example, bispecific antibodies have  
5 been produced using leucine zippers. Kostelny *et al.*, *J. Immunol.*, 148(5):1547-1553 (1992). The leucine zipper peptides from the Fos and Jun proteins were linked to the Fab' portions of two different antibodies by gene fusion. The antibody homodimers were reduced at the hinge region to form monomers and then re-oxidized to form the antibody heterodimers. This method can also be utilized for the production of antibody homodimers. The "diabody" technology described  
10 by Hollinger *et al.*, *Proc. Natl. Acad. Sci. USA*, 90:6444-6448 (1993) has provided an alternative mechanism for making bispecific antibody fragments. The fragments comprise a heavy-chain variable domain ( $V_H$ ) connected to a light-chain variable domain ( $V_L$ ) by a linker which is too short to allow pairing between the two domains on the same chain. Accordingly, the  $V_H$  and  $V_L$  domains of one fragment are forced to pair with the complementary  $V_L$  and  $V_H$  domains of another fragment, thereby forming two antigen-binding sites. Another strategy for making  
15 bispecific antibody fragments by the use of single-chain Fv (sFv) dimers has also been reported. See Gruber *et al.*, *J. Immunol.*, 152:5368 (1994).

Antibodies with more than two valencies are contemplated. For example, trispecific antibodies can be prepared. Tutt *et al.* *J. Immunol.* 147: 60 (1991).

20 (vi) *Screening for antibodies with the desired properties*

Techniques for generating antibodies have been described above. Those antibodies having the characteristics described herein are selected.

To select for antibodies which induce cell death, loss of membrane integrity as indicated by, e.g., PI, trypan blue or 7AAD uptake is assessed relative to control. The preferred assay is  
25 the "PI uptake assay using BT474 cells". According to this assay, BT474 cells (which can be obtained from the American Type Culture Collection (Rockville, MD)) are cultured in Dulbecco's Modified Eagle Medium (D-MEM):Ham's F-12 (50:50) supplemented with 10% heat-inactivated FBS (Hyclone) and 2 mM L-glutamine. (Thus, the assay is performed in the absence of complement and immune effector cells). The BT474 cells are seeded at a density of  $3 \times 10^6$  per  
30 dish in 100 x 20 mm dishes and allowed to attach overnight. The medium is then removed and replaced with fresh medium alone or medium containing 10 $\mu$ g/ml of the appropriate MAb. The

cells are incubated for a 3 day time period. Following each treatment, monolayers are washed with PBS and detached by trypsinization. Cells are then centrifuged at 1200rpm for 5 minutes at 4°C, the pellet resuspended in 3 ml ice cold Ca<sup>2+</sup> binding buffer (10 mM Hepes, pH 7.4, 140 mM NaCl, 2.5 mM CaCl<sub>2</sub>) and aliquoted into 35 mm strainer-capped 12 x 75 tubes (1ml per tube, 3 tubes per treatment group) for removal of cell clumps. Tubes then receive PI (10µg/ml).

- 5 Samples may be analyzed using a FACSCAN™ flow cytometer and FACS CONVERT™ CellQuest software (Becton Dickinson). Those antibodies which induce statistically significant levels of cell death as determined by PI uptake are selected.

In order to select for antibodies which induce apoptosis, an "annexin binding assay using BT474 cells" as described in Example 2 below is available. The BT474 cells are cultured and seeded in dishes as discussed in the preceding paragraph. The medium is then removed and replaced with fresh medium alone or medium containing 10µg/ml of the MAb. Following a three day incubation period, monolayers are washed with PBS and detached by trypsinization. Cells are then centrifuged, resuspended in Ca<sup>2+</sup> binding buffer and aliquoted into tubes as discussed above for the cell death assay. Tubes then receive labelled annexin (e.g. annexin V-FTIC) (1µg/ml). Samples may be analyzed using a FACSCAN™ flow cytometer and FACS CONVERT™ CellQuest software (Becton Dickinson). Those antibodies which induce statistically significant levels of annexin binding relative to control are selected as apoptosis-inducing antibodies.

In addition to the annexin binding assay discussed in the preceding paragraph, a "DNA staining assay using BT474 cells" is available. In order to perform this assay, BT474 cells which have been treated with the antibody of interest as described in the preceding two paragraphs are incubated with 9µg/ml HOECHST 33342™ for 2 hr at 37°C, then analyzed on an EPICS ELITE™ flow cytometer (Coulter Corporation) using MODFIT LT™ software (Verity Software House). Antibodies which induce a change in the percentage of apoptotic cells which is 2 fold or greater (and preferably 3 fold or greater) than untreated cells (up to 100% apoptotic cells) may be selected as pro-apoptotic antibodies using this assay.

To screen for antibodies which bind to an epitope on ErbB2 bound by an antibody of interest, a routine cross-blocking assay such as that described in *Antibodies, A Laboratory Manual*, Cold Spring Harbor Laboratory, Ed Harlow and David Lane (1988), can be performed.

30 Alternatively, epitope mapping described in Example 2 can be performed.

To identify anti-ErbB2 antibodies which inhibit growth of SKBR3 cells in cell culture by

50-100%, the SKBR3 assay described in WO89/06692 can be performed. According to this assay, SKBR3 cells are grown in a 1:1 mixture of F12 and DMEM medium supplemented with 10% fetal bovine serum, glutamine and penicillin/streptomycin. The SKBR3 cells are plated at 20,000 cells in a 35mm cell culture dish (2mls/35mm dish). 2.5 $\mu$ g/ml of the anti-ErbB2 antibody is added per dish. After six days, the number of cells, compared to untreated cells are counted  
5 using an electronic COULTER™ cell counter. Those antibodies which inhibit growth of the SKBR3 cells by 50-100% are selected for combination with the apoptotic antibodies as desired.

(vii) *Effector function engineering*

It may be desirable to modify the antibody of the invention with respect to effector function, so as to enhance the effectiveness of the antibody in treating cancer, for example. For example cysteine residue(s) may be introduced in the Fc region, thereby allowing interchain disulfide bond formation in this region. The homodimeric antibody thus generated may have improved internalization capability and/or increased complement-mediated cell killing and antibody-dependent cellular cytotoxicity (ADCC). See Caron *et al.*, *J. Exp Med.* 176:1191-1195 (1992) and Shopes, *B. J. Immunol.* 148:2918-2922 (1992). Homodimeric antibodies with enhanced anti-tumor activity may also be prepared using heterobifunctional cross-linkers as described in Wolff *et al.* *Cancer Research* 53:2560-2565 (1993). Alternatively, an antibody can be engineered which has dual Fc regions and may thereby have enhanced complement lysis and ADCC capabilities. See Stevenson *et al.* *Anti-Cancer Drug Design* 3:219-230 (1989).

(viii) *Immunoconjugates*

The invention also pertains to immunoconjugates comprising the antibody described herein conjugated to a cytotoxic agent such as a chemotherapeutic agent, toxin (e.g. an enzymatically active toxin of bacterial, fungal, plant or animal origin, or fragments thereof), or a radioactive isotope (*i.e.*, a radioconjugate).

Chemotherapeutic agents useful in the generation of such immunoconjugates have been described above. Enzymatically active toxins and fragments thereof which can be used include diphtheria A chain, nonbinding active fragments of diphtheria toxin, exotoxin A chain (from *Pseudomonas aeruginosa*), ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, *Aleurites fordii* proteins, dianthin proteins, *Phytolaca americana* proteins (PAPI, PAPII, and PAP-S), momordica charantia inhibitor, curcin, crotin, sapaonaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin and the trichothecenes. A variety of radionuclides are available for the production of radioconjugated anti-ErbB2 antibodies. Examples include

<sup>212</sup>Bi, <sup>131</sup>I, <sup>131</sup>In, <sup>90</sup>Y and <sup>186</sup>Re.

Conjugates of the antibody and cytotoxic agent are made using a variety of bifunctional protein coupling agents such as N-succinimidyl-3-(2-pyridyldithiol) propionate (SPDP), iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCL), active esters (such as disuccinimidyl suberate), aldehydes (such as glutaraldehyde), bis-azido compounds (such as bis (p-azidobenzoyl) hexanediamine), bis-diazonium derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such as tolyene 2,6-diisocyanate), and bis-active fluorine compounds (such as 1,5-difluoro-2,4-dinitrobenzene). For example, a ricin immunotoxin can be prepared as described in Vitetta *et al.* *Science* 238: 1098 (1987). Carbon-14-labeled 1-isothiocyanatobenzyl-3-methyldiethylene triaminepentaacetic acid (MX-DTPA) is an exemplary chelating agent for conjugation of radionucleotide to the antibody. See WO94/11026.

In another embodiment, the antibody may be conjugated to a "receptor" (such as streptavidin) for utilization in tumor pretargeting wherein the antibody-receptor conjugate is administered to the patient, followed by removal of unbound conjugate from the circulation using a clearing agent and then administration of a "ligand" (e.g. avidin) which is conjugated to a cytotoxic agent (e.g. a radionucleotide).

(ix) *Immunoliposomes*

The anti-ErbB2 antibodies disclosed herein may also be formulated as immunoliposomes. Liposomes containing the antibody are prepared by methods known in the art, such as described in Epstein *et al.*, *Proc. Natl. Acad. Sci. USA*, 82:3688 (1985); Hwang *et al.*, *Proc. Natl. Acad. Sci. USA*, 77:4030 (1980); and U.S. Pat. Nos. 4,485,045 and 4,544,545. Liposomes with enhanced circulation time are disclosed in U.S. Patent No. 5,013,556.

Particularly useful liposomes can be generated by the reverse phase evaporation method with a lipid composition comprising phosphatidylcholine, cholesterol and PEG-derivatized phosphatidylethanolamine (PEG-PE). Liposomes are extruded through filters of defined pore size to yield liposomes with the desired diameter. Fab' fragments of the antibody of the present invention can be conjugated to the liposomes as described in Martin *et al.* *J. Biol. Chem.* 257: 286-288 (1982) via a disulfide interchange reaction. A chemotherapeutic agent (such as Doxorubicin) is optionally contained within the liposome. See Gabizon *et al.* *J. National Cancer Inst.* 81(19)1484 (1989)

(x) *Antibody Dependent Enzyme Mediated Prodrug Therapy (ADEPT)*

The antibody of the present invention may also be used in ADEPT by conjugating the antibody to a prodrug-activating enzyme which converts a prodrug (e.g. a peptidyl chemotherapeutic agent, see WO81/01145) to an active anti-cancer drug. See, for example, WO 88/07378 and U.S. Patent No. 4,975,278.

5       The enzyme component of the immunoconjugate useful for ADEPT includes any enzyme capable of acting on a prodrug in such a way so as to convert it into its more active, cytotoxic form.

Enzymes that are useful in the method of this invention include, but are not limited to, alkaline phosphatase useful for converting phosphate-containing prodrugs into free drugs; arylsulfatase useful for converting sulfate-containing prodrugs into free drugs; cytosine 10 deaminase useful for converting non-toxic 5-fluorocytosine into the anti-cancer drug, 5-fluorouracil; proteases, such as serratia protease, thermolysin, subtilisin, carboxypeptidases and cathepsins (such as cathepsins B and L), that are useful for converting peptide-containing prodrugs into free drugs; D-alanylcarboxypeptidases, useful for converting prodrugs that contain 15 D-amino acid substituents; carbohydrate-cleaving enzymes such as  $\beta$ -galactosidase and neuraminidase useful for converting glycosylated prodrugs into free drugs;  $\beta$ -lactamase useful for converting drugs derivatized with  $\beta$ -lactams into free drugs; and penicillin amidases, such as penicillin V amidase or penicillin G amidase, useful for converting drugs derivatized at their 20 amine nitrogens with phenoxyacetyl or phenylacetyl groups, respectively, into free drugs. Alternatively, antibodies with enzymatic activity, also known in the art as "abzymes", can be used to convert the prodrugs of the invention into free active drugs (see, e.g., Massey, *Nature* 328: 457-458 (1987)). Antibody-abzyme conjugates can be prepared as described herein for delivery of the abzyme to a tumor cell population.

25       The enzymes of this invention can be covalently bound to the anti-ErbB2 antibodies by techniques well known in the art such as the use of the heterobifunctional crosslinking reagents discussed above. Alternatively, fusion proteins comprising at least the antigen binding region of an antibody of the invention linked to at least a functionally active portion of an enzyme of the invention can be constructed using recombinant DNA techniques well known in the art (see, e.g., Neuberger *et al.*, *Nature*, 312: 604-608 (1984)).

(xi) *Antibody-salvage receptor binding epitope fusions.*

30       In certain embodiments of the invention, it may be desirable to use an antibody fragment, rather than an intact antibody, to increase tumor penetration, for example. In this case, it may

be desirable to modify the antibody fragment in order to increase its serum half life. This may be achieved, for example, by incorporation of a salvage receptor binding epitope into the antibody fragment (e.g. by mutation of the appropriate region in the antibody fragment or by incorporating the epitope into a peptide tag that is then fused to the antibody fragment at either end or in the middle, e.g., by DNA or peptide synthesis).

5 A systematic method for preparing such an antibody variant having an increased *in vivo* half-life comprises several steps. The first involves identifying the sequence and conformation of a salvage receptor binding epitope of an Fc region of an IgG molecule. Once this epitope is identified, the sequence of the antibody of interest is modified to include the sequence and conformation of the identified binding epitope. After the sequence is mutated, the antibody

10 variant is tested to see if it has a longer *in vivo* half-life than that of the original antibody. If the antibody variant does not have a longer *in vivo* half-life upon testing, its sequence is further altered to include the sequence and conformation of the identified binding epitope. The altered antibody is tested for longer *in vivo* half-life, and this process is continued until a molecule is obtained that exhibits a longer *in vivo* half-life.

15 The salvage receptor binding epitope being thus incorporated into the antibody of interest is any suitable such epitope as defined above, and its nature will depend, e.g., on the type of antibody being modified. The transfer is made such that the antibody of interest still possesses the biological activities described herein.

20 The epitope preferably constitutes a region wherein any one or more amino acid residues from one or two loops of a Fc domain are transferred to an analogous position of the antibody fragment. Even more preferably, three or more residues from one or two loops of the Fc domain are transferred. Still more preferred, the epitope is taken from the CH2 domain of the Fc region (e.g., of an IgG) and transferred to the CH1, CH3, or V<sub>H</sub> region, or more than one such region, of the antibody. Alternatively, the epitope is taken from the CH2 domain of the Fc region and transferred to the C<sub>L</sub> region or V<sub>L</sub> region, or both, of the antibody fragment.

25 In one most preferred embodiment, the salvage receptor binding epitope comprises the sequence (5' to 3'): PKNSSMISNTP (SEQ ID NO:5), and optionally further comprises a sequence selected from the group consisting of HQSLGTQ (SEQ ID NO:6), HQNLSDGK (SEQ ID NO:7), HQNISDGK (SEQ ID NO:8), or VISSH LGQQ (SEQ ID NO:9), particularly where the antibody fragment is a Fab or F(ab')<sub>2</sub>. In another most preferred embodiment, the salvage receptor binding epitope is a polypeptide containing the sequence(s)(5' to 3'): HQNLSDGK (SEQ ID

NO:7), HQNISDGK (SEQ ID NO:8), or VISSHGQQ (SEQ ID NO:9) and the sequence: PKNSSMISNTP (SEQ ID NO:5).

**B. Vectors, Host Cells and Recombinant Methods**

The invention also provides isolated nucleic acid encoding an antibody as disclosed herein, vectors and host cells comprising the nucleic acid, and recombinant techniques for the production of the antibody. In addition to recombinant production of the antibody, the nucleic acid encoding the antibodies disclosed herein may be used to inhibit cell surface expression of the ErbB2 protein according to the teachings of WO96/07321, published March 14, 1996, for example. For example, the antibody may be a single chain Fv fragment provided in an expression vector (such as a viral or plasmid vector), which vector is introduced into a cell so as to bind to the ErbB2 protein intracellularly and thereby induce death of the cell.

For recombinant production of the antibody, the nucleic acid encoding it is isolated and inserted into a replicable vector for further cloning (amplification of the DNA) or for expression. DNA encoding the monoclonal antibody is readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of the antibody). Many vectors are available. The vector components preferably include, but are not limited to, one or more of the following: a signal sequence, an origin of replication, one or more marker genes, an enhancer element, a promoter, and a transcription termination sequence.

(i) *Signal sequence component*

The anti-ErbB2 antibody of this invention may be produced recombinantly not only directly, but also as a fusion polypeptide with a heterologous polypeptide, which is preferably a signal sequence or other polypeptide having a specific cleavage site at the N-terminus of the mature protein or polypeptide. The heterologous signal sequence selected preferably is one that is recognized and processed (*i.e.*, cleaved by a signal peptidase) by the host cell. For prokaryotic host cells that do not recognize and process the native anti-ErbB2 antibody signal sequence, the signal sequence is substituted by a prokaryotic signal sequence selected, for example, from the group of the alkaline phosphatase, penicillinase, Ipp, or heat-stable enterotoxin II leaders. For yeast secretion the native signal sequence may be substituted by, e.g., the yeast invertase leader,  $\alpha$  factor leader (including *Saccharomyces* and *Kluyveromyces*  $\alpha$ -factor leaders), or acid phosphatase leader, the *C. albicans* glucoamylase leader, or the signal described in WO 90/13646. In mammalian cell expression, mammalian signal sequences as

well as viral secretory leaders, for example, the herpes simplex gD signal, are available.

The DNA for such precursor region is ligated in reading frame to DNA encoding the anti-ErbB2 antibody.

(ii) *Origin of replication component*

Both expression and cloning vectors contain a nucleic acid sequence that enables the vector to replicate in one or more selected host cells. Preferably, in cloning vectors this sequence is one that enables the vector to replicate independently of the host chromosomal DNA, and includes origins of replication or autonomously replicating sequences. Such sequences are well known for a variety of bacteria, yeast, and viruses. The origin of replication from the plasmid pBR322 is suitable for most Gram-negative bacteria, the 2 $\mu$  plasmid origin is suitable for yeast, and various viral origins (SV40, polyoma, adenovirus, VSV or BPV) are useful for cloning vectors in mammalian cells. Preferably, the origin of replication component is not needed for mammalian expression vectors (the SV40 origin may typically be used only because it contains the early promoter).

(iii) *Selection gene component*

Expression and cloning vectors may contain a selection gene, also termed a selectable marker. Typical selection genes encode proteins that (a) confer resistance to antibiotics or other toxins, e.g., ampicillin, neomycin, methotrexate, or tetracycline, (b) complement auxotrophic deficiencies, or (c) supply critical nutrients not available from complex media, e.g., the gene encoding D-alanine racemase for *Bacilli*.

One example of a selection scheme utilizes a drug to arrest growth of a host cell. Those cells that are successfully transformed with a heterologous gene produce a protein conferring drug resistance and thus survive the selection regimen. Examples of such dominant selection use the drugs neomycin, mycophenolic acid and hygromycin.

Another example of suitable selectable markers for mammalian cells are those that enable the identification of cells competent to take up the anti-ErbB2 antibody nucleic acid, such as DHFR, thymidine kinase, metallothionein-I and -II, preferably primate metallothionein genes, adenosine deaminase, ornithine decarboxylase, etc.

For example, cells transformed with the DHFR selection gene are first identified by culturing all of the transformants in a culture medium that contains methotrexate (Mtx), a competitive antagonist of DHFR. An appropriate host cell when wild-type DHFR is employed is the Chinese hamster ovary (CHO) cell line deficient in DHFR activity.

Alternatively, host cells (particularly wild-type hosts that contain endogenous DHFR) transformed or co-transformed with DNA sequences encoding anti-ErbB2 antibody, wild-type DHFR protein, and another selectable marker such as aminoglycoside 3'-phosphotransferase (APH) can be selected by cell growth in medium containing a selection agent for the selectable marker such as an aminoglycosidic antibiotic, e.g., kanamycin, neomycin, or G418. See U.S.

5 Patent No. 4,965,199.

A suitable selection gene for use in yeast is the *trp1* gene present in the yeast plasmid YRp7 (Stinchcomb *et al.*, *Nature*, 282:39 (1979)). The *trp1* gene provides a selection marker for a mutant strain of yeast lacking the ability to grow in tryptophan, for example, ATCC No. 44076 or PEP4-1. Jones, *Genetics*, 85:12 (1977). The presence of the *trp1* lesion in the yeast host cell genome then provides an effective environment for detecting transformation by growth in the absence of tryptophan. Similarly, *Leu2*-deficient yeast strains (ATCC 20,622 or 38,626) are complemented by known plasmids bearing the *Leu2* gene.

In addition, vectors derived from the 1.6 $\mu$ m circular plasmid pKD1 can be used for transformation of *Kluyveromyces* yeasts. Alternatively, an expression system for large-scale production of recombinant calf chymosin was reported for *K. lactis*. Van den Berg, *Bio/Technology*, 8:135 (1990). Stable multi-copy expression vectors for secretion of mature recombinant human serum albumin by industrial strains of *Kluyveromyces* have also been disclosed. Fleer *et al.*, *Bio/Technology*, 9:968-975 (1991).

20 (iv) *Promoter component*

Expression and cloning vectors usually contain a promoter that is recognized by the host organism and is operably linked to the anti-ErbB2 antibody nucleic acid. Promoters suitable for use with prokaryotic hosts include the *phoA* promoter,  $\beta$ -lactamase and lactose promoter systems, alkaline phosphatase, a tryptophan (*trp*) promoter system, and hybrid promoters such as the tac promoter. However, other known bacterial promoters are suitable. Promoters for use in bacterial systems also will contain a Shine-Dalgarno (S.D.) sequence operably linked to the DNA encoding the anti-ErbB2 antibody.

Promoter sequences are known for eukaryotes. Virtually all eukaryotic genes have an AT-rich region located approximately 25 to 30 bases upstream from the site where transcription is initiated. Another sequence found 70 to 80 bases upstream from the start of transcription of many genes is a CNCAAT region where N may be any nucleotide. At the 3' end of most eukaryotic genes is an AATAAA sequence that may be the signal for addition of the poly A tail

to the 3' end of the coding sequence. All of these sequences are suitably inserted into eukaryotic expression vectors.

Examples of suitable promoting sequences for use with yeast hosts include the promoters for 3-phosphoglycerate kinase or other glycolytic enzymes, such as enolase, glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose-6-phosphate isomerase, 3-phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase, phosphoglucose isomerase, and glucokinase.

Other yeast promoters, which are inducible promoters having the additional advantage of transcription controlled by growth conditions, are the promoter regions for alcohol dehydrogenase 2, isocytochrome C, acid phosphatase, degradative enzymes associated with nitrogen metabolism, metallothionein, glyceraldehyde-3-phosphate dehydrogenase, and enzymes responsible for maltose and galactose utilization. Suitable vectors and promoters for use in yeast expression are further described in EP 73,657. Yeast enhancers also are advantageously used with yeast promoters.

Anti-ErbB2 antibody transcription from vectors in mammalian host cells is controlled, for example, by promoters obtained from the genomes of viruses such as polyoma virus, fowlpox virus, adenovirus (such as Adenovirus 2), bovine papilloma virus, avian sarcoma virus, cytomegalovirus, a retrovirus, hepatitis-B virus and most preferably Simian Virus 40 (SV40), from heterologous mammalian promoters, e.g., the actin promoter or an immunoglobulin promoter, from heat-shock promoters, provided such promoters are compatible with the host cell systems.

The early and late promoters of the SV40 virus are conveniently obtained as an SV40 restriction fragment that also contains the SV40 viral origin of replication. The immediate early promoter of the human cytomegalovirus is conveniently obtained as a HindIII E restriction fragment. A system for expressing DNA in mammalian hosts using the bovine papilloma virus as a vector is disclosed in U.S. Patent No. 4,419,446. A modification of this system is described in U.S. Patent No. 4,601,978. See also Reyes *et al.*, *Nature*, 297:598-601 (1982) on expression of human  $\beta$ -interferon cDNA in mouse cells under the control of a thymidine kinase promoter from herpes simplex virus. Alternatively, the rous sarcoma virus long terminal repeat can be used as the promoter.

(v) *Enhancer element component*

Transcription of a DNA encoding the anti-ErbB2 antibody of this invention by higher eukaryotes is often increased by inserting an enhancer sequence into the vector. Many

enhancer sequences are now known from mammalian genes (globin, elastase, albumin,  $\alpha$ -fetoprotein, and insulin). Typically, however, one will use an enhancer from a eukaryotic cell virus. Examples include the SV40 enhancer on the late side of the replication origin (bp 100-270), the cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and adenovirus enhancers. See also Yaniv, *Nature*, 297:17-18 (1982) on enhancing elements for activation of eukaryotic promoters. The enhancer may be spliced into the vector at a position 5' or 3' to the anti-ErbB2 antibody-encoding sequence, but is preferably located at a site 5' from the promoter.

(vi) *Transcription termination component*

Expression vectors used in eukaryotic host cells (yeast, fungi, insect, plant, animal, human, or nucleated cells from other multicellular organisms) will also contain sequences necessary for the termination of transcription and for stabilizing the mRNA. Such sequences are commonly available from the 5' and, occasionally 3', untranslated regions of eukaryotic or viral DNAs or cDNAs. These regions contain nucleotide segments transcribed as polyadenylated fragments in the untranslated portion of the mRNA encoding anti-ErbB2 antibody. One useful transcription termination component is the bovine growth hormone polyadenylation region. See WO94/11026 and the expression vector disclosed therein.

**(vii) Selection and transformation of host cells**

Suitable host cells for cloning or expressing the DNA in the vectors herein are the prokaryote, yeast, or higher eukaryote cells described above. Suitable prokaryotes for this purpose include eubacteria, such as Gram-negative or Gram-positive organisms, for example, Enterobacteriaceae such as *Escherichia*, e.g., *E. coli*, *Enterobacter*, *Erwinia*, *Klebsiella*, *Proteus*, *Salmonella*, e.g., *Salmonella typhimurium*, *Serratia*, e.g., *Serratia marcescans*, and *Shigella*, as well as *Bacilli* such as *B. subtilis* and *B. licheniformis* (e.g., *B. licheniformis* 41P disclosed in DD 266,710 published 12 April 1989), *Pseudomonas* such as *P. aeruginosa*, and *Streptomyces*. One preferred *E. coli* cloning host is *E. coli* 294 (ATCC 31,446), although other strains such as *E. coli* B, *E. coli* X1776 (ATCC 31,537), and *E. coli* W3110 (ATCC 27,325) are suitable. These examples are illustrative rather than limiting.

In addition to prokaryotes, eukaryotic microbes such as filamentous fungi or yeast are suitable cloning or expression hosts for anti-ErbB2 antibody-encoding vectors. *Saccharomyces cerevisiae*, or common baker's yeast, is the most commonly used among lower eukaryotic host microorganisms. However, a number of other genera, species, and strains are commonly

available and useful herein, such as *Schizosaccharomyces pombe*; *Kluyveromyces* hosts such as, e.g., *K. lactis*, *K. fragilis* (ATCC 12,424), *K. bulgaricus* (ATCC 16,045), *K. wickeramii* (ATCC 24,178), *K. waltii* (ATCC 56,500), *K. drosophilicarum* (ATCC 36,906), *K. thermotolerans*, and *K. marxianus*; *yarrowia* (EP 402,226); *Pichia pastoris* (EP 183,070); *Candida*; *Trichoderma reesiae* (EP 244,234); *Neurospora crassa*; *Schwanniomyces* such as *Schwanniomyces occidentalis*; and 5 filamentous fungi such as, e.g., *Neurospora*, *Penicillium*, *Tolypocladium*, and *Aspergillus* hosts such as *A. nidulans* and *A. niger*.

Suitable host cells for the expression of glycosylated anti-ErbB2 antibody are derived from multicellular organisms. Examples of invertebrate cells include plant and insect cells. Numerous baculoviral strains and variants and corresponding permissive insect host cells from 10 hosts such as *Spodoptera frugiperda* (caterpillar), *Aedes aegypti* (mosquito), *Aedes albopictus* (mosquito), *Drosophila melanogaster* (fruitfly), and *Bombyx mori* have been identified. A variety of viral strains for transfection are publicly available, e.g., the L-1 variant of *Autographa californica* NPV and the Bm-5 strain of *Bombyx mori* NPV, and such viruses may be used as the virus herein according to the present invention, particularly for transfection of *Spodoptera frugiperda* cells.

Plant cell cultures of cotton, corn, potato, soybean, petunia, tomato, and tobacco can also be utilized as hosts.

However, interest has been greatest in vertebrate cells, and propagation of vertebrate cells in culture (tissue culture) has become a routine procedure. Examples of useful mammalian 20 host cell lines are monkey kidney CV1 line transformed by SV40 (COS-7, ATCC CRL 1651); human embryonic kidney line (293 or 293 cells subcloned for growth in suspension culture, Graham et al., *J. Gen Virol.*, 36:59 (1977)); baby hamster kidney cells (BHK, ATCC CCL 10); Chinese hamster ovary cells/-DHFR (CHO, Urlaub et al., *Proc. Natl. Acad. Sci. USA*, 77:4216 (1980)); mouse sertoli cells (TM4, Mather, *Biol. Reprod.*, 23:243-251 (1980)); monkey kidney 25 cells (CV1 ATCC CCL 70); African green monkey kidney cells (VERO-76, ATCC CRL-1587); human cervical carcinoma cells (HELA, ATCC CCL 2); canine kidney cells (MDCK, ATCC CCL 34); buffalo rat liver cells (BRL 3A, ATCC CRL 1442); human lung cells (W138, ATCC CCL 75); human liver cells (Hep G2, HB 8065); mouse mammary tumor (MMT 060562, ATCC CCL51); TRI 30 cells (Mather et al., *Annals N.Y. Acad. Sci.*, 383:44-68 (1982)); MRC 5 cells; FS4 cells; and a human hepatoma line (Hep G2).

Host cells are transformed with the above-described expression or cloning vectors for

anti-ErbB2 antibody production and cultured in conventional nutrient media modified as appropriate for inducing promoters, selecting transformants, or amplifying the genes encoding the desired sequences.

(viii) *Culturing the host cells*

The host cells used to produce the anti-ErbB2 antibody of this invention may be cultured in a variety of media. Commercially available media such as Ham's F10 (Sigma), Minimal Essential Medium ((MEM), (Sigma), RPMI-1640 (Sigma), and Dulbecco's Modified Eagle's Medium ((DMEM), Sigma) are suitable for culturing the host cells. In addition, any of the media described in Ham *et al.* *Meth. Enz.*, 58:44 (1979), Barnes *et al.*, *Anal. Biochem.*, 102:255 (1980), U.S. Pat. Nos. 4,767,704; 4,657,866; 4,927,762; 4,560,655; or 5,122,469; WO 90/03430; WO 87/00195; or U.S. Patent Re. 30,985 may be used as culture media for the host cells. Any of these media may be supplemented as necessary with hormones and/or other growth factors (such as insulin, transferrin, or epidermal growth factor), salts (such as sodium chloride, calcium, magnesium, and phosphate), buffers (such as HEPES), nucleotides (such as adenosine and thymidine), antibiotics (such as GENTAMYCIN™ drug), trace elements (defined as inorganic compounds usually present at final concentrations in the micromolar range), and glucose or an equivalent energy source. Any other necessary supplements may also be included at appropriate concentrations that would be known to those skilled in the art. The culture conditions, such as temperature, pH, and the like, are those previously used with the host cell selected for expression, and will be apparent to the ordinarily skilled artisan.

(ix) *Purification of anti-ErbB2 antibody*

When using recombinant techniques, the antibody can be produced intracellularly, in the periplasmic space, or directly secreted into the medium. If the antibody is produced intracellularly, as a first step, the particulate debris, either host cells or lysed fragments, is removed, for example, by centrifugation or ultrafiltration. Carter *et al.*, *Bio/Technology* 10:163-167 (1992) describe a procedure for isolating antibodies which are secreted to the periplasmic space of *E. coli*. Briefly, cell paste is thawed in the presence of sodium acetate (pH 3.5), EDTA, and phenylmethylsulfonylfluoride (PMSF) over about 30 min. Cell debris can be removed by centrifugation. Where the antibody is secreted into the medium, supernatants from such expression systems are preferably first concentrated using a commercially available protein concentration filter, for example, an Amicon or Millipore Pellicon ultrafiltration unit. A protease inhibitor such as PMSF may be included in any of the foregoing steps to inhibit proteolysis and

antibiotics may be included to prevent the growth of adventitious contaminants.

The antibody composition prepared from the cells can be purified using, for example, hydroxylapatite chromatography, gel electrophoresis, dialysis, and affinity chromatography, with affinity chromatography being the preferred purification technique. The suitability of protein A as an affinity ligand depends on the species and isotype of any immunoglobulin Fc domain that is present in the antibody. Protein A can be used to purify antibodies that are based on human  $\gamma$ 1,  $\gamma$ 2, or  $\gamma$ 4 heavy chains (Lindmark *et al.*, *J. Immunol. Meth.* 62:1-13 (1983)). Protein G is recommended for all mouse isotypes and for human  $\gamma$ 3 (Guss *et al.*, *EMBO J.* 5:1567-1575 (1986)). The matrix to which the affinity ligand is attached is most often agarose, but other matrices are available. Mechanically stable matrices such as controlled pore glass or poly(styrenedivinyl)benzene allow for faster flow rates and shorter processing times than can be achieved with agarose. Where the antibody comprises a C<sub>H</sub>3 domain, the Bakerbond ABX™resin (J. T. Baker, Phillipsburg, NJ) is useful for purification. Other techniques for protein purification such as fractionation on an ion-exchange column, ethanol precipitation, Reverse Phase HPLC, chromatography on silica, chromatography on heparin SEPHAROSE™ chromatography on an anion or cation exchange resin (such as a polyaspartic acid column), chromatofocusing, SDS-PAGE, and ammonium sulfate precipitation are also available depending on the antibody to be recovered.

Following any preliminary purification step(s), the mixture comprising the antibody of interest and contaminants may be subjected to low pH hydrophobic interaction chromatography using an elution buffer at a pH between about 2.5-4.5, preferably performed at low salt concentrations (e.g. from about 0-0.25M salt).

### C. Pharmaceutical Formulations

Therapeutic formulations of the antibody are prepared for storage by mixing the antibody having the desired degree of purity with optional pharmaceutically acceptable carriers, excipients or stabilizers (*Remington's Pharmaceutical Sciences* 16th edition, Osol, A. Ed. (1980)), in the form of lyophilized formulations or aqueous solutions. Acceptable carriers, excipients, or stabilizers are nontoxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride, benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-

pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose or sorbitol; salt-forming counter-ions such as sodium; metal complexes (e.g. Zn-protein complexes); and/or non-ionic surfactants such as TWEEN™, PLURONICS™ or polyethylene glycol (PEG).

The formulation herein may also contain more than one active compound as necessary for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other. For example, it may be desirable to further provide antibodies which bind to EGFR, ErbB2 (e.g. an antibody which binds a different epitope on ErbB2), ErbB3, ErbB4, or vascular endothelial factor (VEGF) in the one formulation. Alternatively, or in addition, the composition may comprise a cytotoxic agent, cytokine or growth inhibitory agent. Such molecules are suitably present in combination in amounts that are effective for the purpose intended.

The active ingredients may also be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsules and poly-(methylmethacrylate) microcapsules, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nanoparticles and nanocapsules) or in macroemulsions. Such techniques are disclosed in *Remington's Pharmaceutical Sciences* 16th edition, Osol, A. Ed. (1980).

The formulations to be used for *in vivo* administration must be sterile. This is readily accomplished by filtration through sterile filtration membranes.

Sustained-release preparations may be prepared. Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the antibody, which matrices are in the form of shaped articles, e.g. films, or microcapsules. Examples of sustained-release matrices include polyesters, hydrogels (for example, poly(2-hydroxyethyl-methacrylate), or poly(vinylalcohol)), polylactides (U.S. Pat. No. 3,773,919), copolymers of L-glutamic acid and  $\gamma$  ethyl-L-glutamate, non-degradable ethylene-vinyl acetate, degradable lactic acid-glycolic acid copolymers such as the LUPRON DEPOT™(injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate), and poly-D-(-)-3-hydroxybutyric acid. While polymers such as ethylene-vinyl acetate and lactic acid-

glycolic acid enable release of molecules for over 100 days, certain hydrogels release proteins for shorter time periods. When encapsulated antibodies remain in the body for a long time, they may denature or aggregate as a result of exposure to moisture at 37°C, resulting in a loss of biological activity and possible changes in immunogenicity. Rational strategies can be devised for stabilization depending on the mechanism involved. For example, if the aggregation mechanism is discovered to be intermolecular S-S bond formation through thio-disulfide interchange, stabilization may be achieved by modifying sulfhydryl residues, lyophilizing from acidic solutions, controlling moisture content, using appropriate additives, and developing specific polymer matrix compositions.

5           **D. Non-therapeutic Uses for the Antibody**

10           The antibodies of the invention may be used as affinity purification agents. In this process, the antibodies are immobilized on a solid phase such a Sephadex resin or filter paper, using methods well known in the art. The immobilized antibody is contacted with a sample containing the ErbB2 protein (or fragment thereof) to be purified, and thereafter the support is washed with a suitable solvent that will remove substantially all the material in the sample except 15           the ErbB2 protein, which is bound to the immobilized antibody. Finally, the support is washed with another suitable solvent, such as glycine buffer, pH 5.0, that will release the ErbB2 protein from the antibody.

20           Anti-ErbB2 antibodies may also be useful in diagnostic assays for ErbB2 protein, e.g., detecting its expression in specific cells, tissues, or serum. Thus, the antibodies may be used in the diagnosis of human malignancies (see, for example, US Patent 5,183,884).

For diagnostic applications, the antibody typically will be labeled with a detectable moiety. Numerous labels are available which can be preferably grouped into the following categories:

25           (a) Radioisotopes, such as <sup>35</sup>S, <sup>14</sup>C, <sup>125</sup>I, <sup>3</sup>H, and <sup>131</sup>I. The antibody can be labeled with the radioisotope using the techniques described in *Current Protocols in Immunology*, Volumes 1 and 2, Coligen et al., Ed., Wiley-Interscience, New York, New York, Pubs., (1991) for example and radioactivity can be measured using scintillation counting.

30           (b) Fluorescent labels such as rare earth chelates (europium chelates) or fluorescein and its derivatives, rhodamine and its derivatives, dansyl, Lissamine, phycoerythrin and Texas Red are available. The fluorescent labels can be conjugated to the antibody using the techniques disclosed in *Current Protocols in Immunology*, supra, for example. Fluorescence can be quantified using a fluorimeter.

(c) Various enzyme-substrate labels are available and U.S. Patent No. 4,275,149 provides a review of some of these. The enzyme preferably catalyses a chemical alteration of the chromogenic substrate which can be measured using various techniques. For example, the enzyme may catalyze a color change in a substrate, which can be measured spectrophotometrically. Alternatively, the enzyme may alter the fluorescence or 5 chemiluminescence of the substrate. Techniques for quantifying a change in fluorescence are described above. The chemiluminescent substrate becomes electronically excited by a chemical reaction and may then emit light which can be measured (using a chemiluminometer, for example) or donates energy to a fluorescent acceptor. Examples of enzymatic labels include 10 luciferases (e.g., firefly luciferase and bacterial luciferase; U.S. Patent No. 4,737,456), luciferin, 2,3-dihydrophthalazinediones, malate dehydrogenase, urease, peroxidase such as horseradish 15 peroxidase (HRPO), alkaline phosphatase,  $\beta$ -galactosidase, glucoamylase, lysozyme, saccharide oxidases (e.g., glucose oxidase, galactose oxidase, and glucose-6-phosphate dehydrogenase), heterocyclic oxidases (such as uricase and xanthine oxidase), lactoperoxidase, microperoxidase, and the like. Techniques for conjugating enzymes to antibodies are described in O'Sullivan et 20 al., Methods for the Preparation of Enzyme-Antibody Conjugates for use in Enzyme Immunoassay, in *Methods in Enzym.* (ed J. Langone & H. Van Vunakis), Academic press, New York, 73: 147-166 (1981).

Examples of enzyme-substrate combinations include, for example:

- (i) Horseradish peroxidase (HRPO) with hydrogen peroxidase as a substrate, wherein 20 the hydrogen peroxidase oxidizes a dye precursor (e.g. orthophenylenediamine (OPD) or 3,3',5,5'-tetramethyl benzidine hydrochloride (TMB));
- (ii) alkaline phosphatase (AP) with para-Nitrophenyl phosphate as chromogenic substrate; and
- (iii)  $\beta$ -D-galactosidase ( $\beta$ -D-Gal) with a chromogenic substrate (e.g. p-nitrophenyl- $\beta$ -D- 25 galactosidase) or fluorogenic substrate 4-methylumbelliferyl- $\beta$ -D-galactosidase.

Numerous other enzyme-substrate combinations are available to those skilled in the art. For a general review of these, see U.S. Patent Nos. 4,275,149 and 4,318,980.

Sometimes, the label is indirectly conjugated with the antibody. The skilled artisan will 30 be aware of various techniques for achieving this. For example, the antibody can be conjugated with biotin and any of the three broad categories of labels mentioned above can be conjugated with avidin, or vice versa. Biotin binds selectively to avidin and thus, the label can be conjugated

with the antibody in this indirect manner. Alternatively, to achieve indirect conjugation of the label with the antibody, the antibody is conjugated with a small hapten (e.g. digoxin) and one of the different types of labels mentioned above is conjugated with an anti-hapten antibody (e.g. anti-digoxin antibody). Thus, indirect conjugation of the label with the antibody can be achieved.

- 5        In another embodiment of the invention, the anti-ErbB2 antibody need not be labeled, and the presence thereof can be detected using a labeled antibody which binds to the ErbB2 antibody.

10      The antibodies of the present invention may be employed in any known assay method, such as competitive binding assays, direct and indirect sandwich assays, and immunoprecipitation assays. Zola, *Monoclonal Antibodies: A Manual of Techniques*, pp.147-158 (CRC Press, Inc., 1987).

15      Competitive binding assays rely on the ability of a labeled standard to compete with the test sample analyte for binding with a limited amount of antibody. The amount of ErbB2 protein in the test sample is inversely proportional to the amount of standard that becomes bound to the antibodies. To facilitate determining the amount of standard that becomes bound, the antibodies preferably are insolubilized before or after the competition, so that the standard and analyte that are bound to the antibodies may conveniently be separated from the standard and analyte which remain unbound.

20      Sandwich assays involve the use of two antibodies, each capable of binding to a different immunogenic portion, or epitope, of the protein to be detected. In a sandwich assay, the test sample analyte is bound by a first antibody which is immobilized on a solid support, and thereafter a second antibody binds to the analyte, thus forming an insoluble three-part complex. See, e.g., US Pat No. 4,376,110. The second antibody may itself be labeled with a detectable moiety (direct sandwich assays) or may be measured using an anti-immunoglobulin antibody that 25 is labeled with a detectable moiety (indirect sandwich assay). For example, one type of sandwich assay is an ELISA assay, in which case the detectable moiety is an enzyme.

For immunohistochemistry, the tumor sample may be fresh or frozen or may be embedded in paraffin and fixed with a preservative such as formalin, for example.

30      The antibodies may also be used for *in vivo* diagnostic assays. Preferably, the antibody is labelled with a radionuclide (such as  $^{111}\text{In}$ ,  $^{99}\text{Tc}$ ,  $^{14}\text{C}$ ,  $^{131}\text{I}$ ,  $^{125}\text{I}$ ,  $^3\text{H}$ ,  $^{32}\text{P}$  or  $^{35}\text{S}$ ) so that the tumor can be localized using immunoscintigraphy.

### **E. Diagnostic Kits**

As a matter of convenience, the antibody of the present invention can be provided in a kit, i.e., a packaged combination of reagents in predetermined amounts with instructions for performing the diagnostic assay. Where the antibody is labelled with an enzyme, the kit will include substrates and cofactors required by the enzyme (e.g. a substrate precursor which provides the detectable chromophore or fluorophore). In addition, other additives may be included such as stabilizers, buffers (e.g. a block buffer or lysis buffer) and the like. The relative amounts of the various reagents may be varied widely to provide for concentrations in solution of the reagents which substantially optimize the sensitivity of the assay. Particularly, the reagents may be provided as dry powders, usually lyophilized, including excipients which on dissolution will provide a reagent solution having the appropriate concentration.

### **F. Therapeutic Uses for the Antibody**

It is contemplated that the anti-ErbB2 antibody of the present invention may be used to treat various conditions, including those characterized by overexpression and/or activation of the ErbB2 receptor. Exemplary conditions or disorders to be treated with the ErbB2 antibody include benign or malignant tumors (e.g. renal, liver, kidney, bladder, breast, gastric, ovarian, colorectal, prostate, pancreatic, lung, vulval, thyroid, hepatic carcinomas; sarcomas; glioblastomas; and various head and neck tumors); leukemias and lymphoid malignancies; other disorders such as neuronal, glial, astrocytal, hypothalamic and other glandular, macrophagal, epithelial, stromal and blastocoelic disorders; and inflammatory, angiogenic and immunologic disorders.

The antibodies of the invention are administered to a mammal, preferably a human, in accord with known methods, such as intravenous administration as a bolus or by continuous infusion over a period of time, by intramuscular, intraperitoneal, intracerebrospinal, subcutaneous, intra-articular, intrasynovial, intrathecal, oral, topical, or inhalation routes. Intravenous administration of the antibody is preferred.

Other therapeutic regimens may be combined with the administration of the anti-ErbB2 antibodies of the instant invention. For example, the patient to be treated with the antibodies disclosed herein may also receive radiation therapy. Alternatively, or in addition, a chemotherapeutic agent may be administered to the patient. Preparation and dosing schedules for such chemotherapeutic agents may be used according to manufacturers' instructions or as determined empirically by the skilled practitioner. Preparation and dosing schedules for such chemotherapy are also described in *Chemotherapy Service Ed.*, M.C. Perry, Williams & Wilkins,

Baltimore, MD (1992). The chemotherapeutic agent may precede, or follow administration of the antibody or may be given simultaneously therewith. The antibody may be combined with an anti-oestrogen compound such as tamoxifen or an anti-progesterone such as onapristone (see, EP 616812) in dosages known for such molecules.

It may be desirable to also administer antibodies against other tumor associated antigens, such as antibodies which bind to the EGFR, ErbB3, ErbB4, or vascular endothelial factor (VEGF). Alternatively, or in addition, two or more anti-ErbB2 antibodies may be co-administered to the patient. Sometimes, it may be beneficial to also administer one or more cytokines to the patient. In a preferred embodiment, the ErbB2 antibody is co-administered with a growth inhibitory agent. For example, the growth inhibitory agent may be administered first, followed by the ErbB2 antibody. However, simultaneous administration or administration of the ErbB2 antibody first is also contemplated. Suitable dosages for the growth inhibitory agent are those presently used and may be lowered due to the combined action (synergy) of the growth inhibitory agent and anti-ErbB2 antibody.

For the prevention or treatment of disease, the appropriate dosage of antibody will depend on the type of disease to be treated, as defined above, the severity and course of the disease, whether the antibody is administered for preventive or therapeutic purposes, previous therapy, the patient's clinical history and response to the antibody, and the discretion of the attending physician. The antibody is suitably administered to the patient at one time or over a series of treatments.

Depending on the type and severity of the disease, about 1 µg/kg to 15 mg/kg (e.g. 0.1-20mg/kg) of antibody is an initial candidate dosage for administration to the patient, whether, for example, by one or more separate administrations, or by continuous infusion. A typical daily dosage might range from about 1 µg/kg to 100 mg/kg or more, depending on the factors mentioned above. For repeated administrations over several days or longer, depending on the condition, the treatment is sustained until a desired suppression of disease symptoms occurs. However, other dosage regimens may be useful. The progress of this therapy is easily monitored by conventional techniques and assays.

#### G. Articles of Manufacture

In another embodiment of the invention, an article of manufacture containing materials useful for the treatment of the disorders described above is provided. The article of manufacture comprises a container and a label. Suitable containers include, for example, bottles, vials,

syringes, and test tubes. The containers may be formed from a variety of materials such as glass or plastic. The container holds a composition which is effective for treating the condition and may have a sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle). The active agent in the composition is the anti-ErbB2 antibody. The label on, or associated with, the container indicates that the composition is used for treating the condition of choice. The article of manufacture may further comprise a second container comprising a pharmaceutically-acceptable buffer, such as phosphate-buffered saline, Ringer's solution and dextrose solution. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, syringes, and package inserts with instructions for use.

10           **H. Deposit of Materials**

The following hybridoma cell lines have been deposited with the American Type Culture Collection, 12301 Parklawn Drive, Rockville, MD, USA (ATCC):

|    | <b>Antibody Designation</b> | <b>ATCC No.</b> | <b>Deposit Date</b> |
|----|-----------------------------|-----------------|---------------------|
|    | 7C2                         | ATCC HB-12215   | October 17, 1996    |
| 15 | 7F3                         | ATCC HB-12216   | October 17, 1996    |
|    | 4D5                         | ATCC CRL 10463  | May 24, 1990        |

These deposits were made under the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purpose of Patent Procedure and the Regulations thereunder (Budapest Treaty). This assures maintenance of viable cultures for 30 years from the date of deposit. The cell lines will be made available by ATCC under the terms of the Budapest Treaty, and subject to an agreement between Genentech, Inc. and ATCC, which assures (a) that access to the cultures will be available during pendency of the patent application to one determined by the Commissioner to be entitled thereto under 37 CFR §1.14 and 35 USC §122, and (b) that all restrictions on the availability to the public of the cultures so deposited will be irrevocably removed upon the granting of the patent.

The assignee of the present application has agreed that if the cultures on deposit should die or be lost or destroyed when cultivated under suitable conditions, they will be promptly replaced on notification with a viable specimen of the same culture. Availability of the deposited cell lines is not to be construed as a license to practice the invention in contravention of the rights granted under the authority of any government in accordance with its patent laws.

The foregoing written specification is considered to be sufficient to enable one skilled in the art to practice the invention. The present invention is not to be limited in scope by the antibodies deposited, since any antibody that is functionally equivalent is within the scope of this invention. The deposit of material herein does not constitute an admission that the written description herein contained is inadequate to enable the practice of any aspect of the invention, 5 including the best mode thereof, nor is it to be construed as limiting the scope of the claims to the specific illustration that it represents. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and fall within the scope of the appended claims.

The following examples are offered by way of illustration and not by way of limitation.

10 The disclosures of all citations in the specification are expressly incorporated herein by reference.

## EXAMPLE 1

### INDUCTION OF CELL DEATH

15 **Cell lines.** The established human breast tumor cells BT474 and MDA-MB-231 (which are available from ATCC) were grown in minimum essential medium (Gibco, Grand Island, NY) supplemented with 10% heat-inactivated fetal bovine serum (FBS) (HyClone, Logan, UT), sodium pyruvate, L-glutamine (2mM), non-essential amino acids and 2x vitamin solution and maintained at 37°C in 5% CO<sub>2</sub> (Zhang *et al.* *Invas. & Metas.* 11(4):204-215 (1991) and Price *et al.* *Cancer Res.* 50(3):717-721 (1990)).

20 **Antibodies.** The anti-ErbB2 IgG<sub>1</sub> murine monoclonal antibodies 4D5 and 7C2, specific for the extracellular domain of ErbB2, were produced as described in Fendly *et al.* *Cancer Research* 50:1550-1558 (1990) and WO89/06692. Briefly, NIH 3T3/HER2-3<sub>400</sub> cells (expressing approximately 1 x 10<sup>5</sup> ErbB2 molecules/cell) produced as described in Hudziak *et al.* *Proc. Natl. Acad. Sci. (USA)* 84:7159 (1987) were harvested with phosphate buffered saline (PBS) containing 25mM EDTA and used to immunize BALB/c mice. The mice were given injections i.p. of 10<sup>7</sup> cells in 0.5ml PBS on weeks, 0, 2, 5 and 7. The mice with antisera that immunoprecipitated <sup>32</sup>P-labeled ErbB2 were given i.p. injections of a wheat germ agglutinin-Sepharose (WGA) purified ErbB2 membrane extract on weeks 9 and 13. This was followed by an i.v. injection of 0.1ml of the ErbB2 preparation and the splenocytes were fused with mouse myeloma line X63-Ag8.653. 25

30 Hybridoma supernatants were screened for ErbB2-binding by ELISA and radioimmunoprecipitation. MOPC-21 (IgG1), (Cappell, Durham, NC), was used as an isotype-

matched control.

**Analysis of cell cycle status and viability.** Cells were simultaneously examined for viability and cell cycle status by flow cytometry on a FACSTAR PLUS™ (Becton Dickinson Immunocytometry Systems USA, San Jose, CA). Breast tumor cells were harvested by washing the monolayer with phosphate buffered saline (PBS), incubating cells in 0.05% trypsin and 0.53 mM EDTA (Gibco) and resuspending them in culture medium. The cells were washed twice with PBS containing 1% FBS and the pellet was incubated for 30 minutes on ice with 50µl of 400µM 7 amino actinomycin D (7AAD) (Molecular Probes, Eugene, OR), a vital dye which stains all permeable cells. Cells were then fixed with 1.0ml of 0.5% paraformaldehyde in PBS and simultaneously permeabilized and stained for 16 hours at 4°C with 220µl of 10µg/ml HOECHST 33342™ dye (also a DNA binding dye) containing 5% TWEEN 20™.

The data from  $1 \times 10^4$  cells were collected and stored using LYSYS II™ software and analyzed using PAINT-A-GATE™ software (Becton Dickinson) (Darzynkiewica *et al.* *Cytometry* 13:795-808 (1992) and Picker *et al.* *J. Immunol.* 150(3):1105-1121 (1993)). The viability and percentage of cells in each stage of the cell cycle were determined on gated single cells using 7AAD and Hoechst staining, respectively. (Cell doublets were excluded by pulse analysis of width vs. area of the Hoechst signal.) Cell numbers were determined using a hemocytometer.

**DNA synthesis.** Triplicate cultures of  $8 \times 10^3$  cells/well were plated in 96-well flat bottom plates, allowed to adhere overnight, then continuously incubated in the presence or absence of anti-ErbB2 or control Ig for different periods of time. During the last 12 hours of culture, wells were pulsed with 1µCi  $^3\text{H}$ -thymidine (Amersham, Arlington, VA).

**Affinity of binding to the extracellular domain of the ErbB2.** Radioiodinated anti-ErbB2 antibodies were prepared by the lodogen method (Fracker *et al.* *Biochem. Biophys. Res. Comm.* 80:849-857 (1978)). Binding assays were performed using monolayers of BT474 cells cultured in 96-well tissue culture plates (Falcon, Becton Dickenson Labware, Lincoln Park, N.J.). The cells were trypsinized and seeded in wells of 96-well plates at a density of  $10^4$  cells/well and allowed to adhere overnight. The monolayers were washed with cold culture medium supplemented with 0.1% sodium azide and then incubated in triplicate with 100µl of serial dilutions of  $^{125}\text{I}$ -anti-ErbB2 antibodies in cold culture medium with 0.1% azide for 4 hours on ice. Non-specific binding was estimated by the preincubation of each sample with a 100-fold molar excess of nonradioactive antibodies in a total volume of 100µl. Unbound radioactivity was removed by two washes with cold medium with 0.1% sodium azide. The cell-associated

radioactivity was detected in a gamma counter after solubilization of the cells with 150 $\mu$ l 0.1 M NaOH/well. The anti-ErbB2 binding constants ( $K_d$ ) were determined by Scatchard analysis.

**Results.** The binding affinities of anti-ErbB2 antibodies (7C2 and 4D5) were determined by Scatchard analysis. The binding constants ( $K_d$ ) were  $6.5 \times 10^{-9}$  M (4D5) and  $2.9 \times 10^{-9}$  M (7C2). Blocking experiments were carried out using unlabelled antibodies followed by FITC-7C2.

5 As shown in Fig. 2, 4D5 reacts with a different epitope than 7C2.

The effect of these antibodies on the growth of the BT474 human breast cancer cells which overexpress ErbB2 was then investigated. Fig. 3A shows the results of flow cytometric analysis of cells incubated with an isotype-matched control. 10-12% of the cells were dead and 28% of the viable cells were in the S-G<sub>2</sub>-M phases of the cell cycle. Similar results were 10 obtained when the cells were incubated in medium alone. Treatment with 4D5 (Fig. 3B) induced a decrease in cell size as measured by forward light scatter, a moderate increase in the proportion of dead cells (27.0%) and a marked decrease of viable cells in S-G<sub>2</sub>-M (6.3%) with a concurrent increase of cells in G<sub>0</sub>/G<sub>1</sub> (94%) as compared to the control cells. Cell counts were reduced by 46.7%. Without being bound to any one theory, it appears that 4D5 induces primarily 15 cell cycle arrest (CCA) in G<sub>0</sub>/G<sub>1</sub>, but that a significant proportion of cells also die. Fig. 3C shows the results of incubating the BT474 cell with 50 $\mu$ g/ml of 7C2. There was no change in forward light scatter of the residual viable cells, a marked increase in the proportion of dead cells (72%) and a 70% decrease in cell count compared to control cells (data not shown). Hence, viable 20 cells were decreased by 85%. There was a slight reduction in cycling cells (21% vs. an average of 29% for controls) but because of extensive cell death, it was difficult to distinguish CCA from a preferential loss of cycling cells. Hence, 7C2 and 4D5 affect cells differently; 7C2 induces predominantly cell death while 4D5 induces predominantly CCA. Fig. 3D shows the results of adding 50 $\mu$ g/ml 7C2 and 1 $\mu$ g/ml 4D5 to BT474 cells simultaneously. There was no increase in the proportion of dead cells compared to cells treated with 7C2 alone (Fig. 3C). However, the 25 number of residual viable cells was reduced by an additional 50%. In addition, there was a marked increase in cells having both permeable membranes and significantly degraded DNA (<1 X). An analysis of the small number of residual viable cells showed that there was a similar reduction in cycling cells compared to cells treated with 4D5 alone (Fig. 3D compared to Fig. 3B).

As an additional control, MDA-MB-231 breast cancer cells, which express normal levels 30 of ErbB2 (Lewis *et al. Cancer Immunol. Immunther.* 37:255-263 (1993)), were treated with 4D5 or 7C2. As compared to the control, neither antibody affected the growth of these cells (27-28%

of viable cells in S-G<sub>2</sub>-M and 12-13% dead cells).

The additive effects of both antibodies was clearly demonstrated when a suboptimal dose of 4D5 (0.05 µg/ml) was used. Fig. 4A shows that thymidine incorporation was reduced by 22.3% and 23% in cells treated with 7C2 and 4D5 respectively, and by 58% in cells treated with 4D5 and 7C2. An additional experiment utilizing 20µg 7C2 and 0.1µg 4D5 gave similar results,  
5 i.e., thymidine incorporation was reduced by 41%, 25% and 72% in cells treated with 7C2 alone, 4D5 alone, or 4D5 plus 7C2, respectively. In Fig. 4B, the viable cell counts are shown. A total cell count was determined and FACS analysis was used to establish the number of viable cells. Viable cell counts were reduced by 64%, 29% and 84% in cells treated with 7C2, 4D5 or the combination, respectively, when compared to untreated controls.

10

## EXAMPLE 2

### INDUCTION OF APOPTOSIS

**Materials and cell culture.** All tumor cell lines were obtained from the American Type Culture Collection (Rockville, MD). Cells were cultured in Dulbecco's Modified Eagle Medium (D-MEM):Ham's F-12 (50:50) supplemented with 10% heat-inactivated fetal bovine serum (FBS) (Hyclone) and 2 mM L-glutamine. Human mammary epithelial cells (HMEC) were obtained from Clonetics and grown in MEGM (mammary epithelial growth medium, Clonetics) containing bovine pituitary extract. Biochemicals used were: annexin V-FTIC (BioWhittaker, Inc.), propidium iodide (PI, Molecular Probes, Inc.), and HOECHST 33342™ (Calbiochem). Anti-ErbB2 monoclonal antibodies (MAbs) were produced as described in Fendly *et al.* *Cancer Research* 50:1550-1558  
15 (1990) and WO89/06692 (see Example 1 above). The anti-ErbB2 MAbs tested are designated:  
20 4D5, 7C2, 7F3, 3H4, 2C4, 2H11, 3E8, and 7D3. The isotype-matched control MAb 1766 is directed against the herpes simplex virus (HSV-1) glycoprotein D.

**Flow cytometry experiments for measuring induction of apoptosis.** Cells were seeded at a density of  $3 \times 10^6$  per dish in 100 x 20 mm dishes and allowed to attach overnight.  
25 The medium was then removed and replaced with fresh medium alone or medium containing 10µg/ml of the appropriate MAb. For most experiments, cells were incubated for a 3 day time period. For time course studies, cells were treated for 0.25, 0.5, 1, 2, 24, 72, 96 hr, 7 or 10 days.  
30 MAb concentrations used in the dose-response experiments were 0.01, 0.1, 1 and 10µg/ml. Following each treatment, supernatants were individually collected and kept on ice, monolayers were detached by trypsinization and pooled with the corresponding supernatant. Cells were then

centrifuged at 1200rpm for 5 minutes at 4°C, the pellet resuspended in 3 ml ice cold Ca<sup>2+</sup> binding buffer (10 mM Hepes, pH 7.4, 140 mM NaCl, 2.5 mM CaCl<sub>2</sub>) and aliquoted into 35 mm strainer-capped 12 x 75 tubes (1ml per tube, 3 tubes per treatment group) for removal of cell aggregates. Each group of 3 tubes then received annexin V-FTIC (1µg/ml) or PI (10µg/ml) or annexin V-FTIC plus PI. Samples were analyzed using a FACSCAN™ flow cytometer and FACSCONVERT™

5 CellQuest software (Becton Dickinson). For cell cycle analysis, cells were incubated with 9µg/ml HOECHST 33342™ for 2 hr at 37°C, then analyzed on an EPICS ELITE™ flow cytometer (Coulter Corporation) using MODFIT LT™ software (Verity Software House).

Serum-deprivation experiments were performed in the following way. BT474 breast tumor cells were seeded in culture medium at a density of 5 x 10<sup>6</sup> per dish in 100 x 20 mm dishes. The following day, the medium was replaced with medium containing 0.1% FBS and the cells were incubated for 3 days. Cells then received 10µg/ml of MAb 7C2 or 4D5 in fresh medium supplemented with 0.1% FBS. After a 3 day incubation, analyses of annexin V binding, PI uptake and cell cycle progression were performed as described above. In order to compare growth of serum-starved cells to non-deprived cells, separate dishes of BT474 cells, incubated in medium supplemented with 10% FBS for all time points, were studied in parallel.

15 **Detection of DNA ladder formation.** For measuring internucleosomal fragmentation of DNA, BT474 breast tumor cells were plated and treated for 3 days with 10 µg/ml MAb 4D5 or 7C2 as described above. DNA was extracted, <sup>32</sup>P-end-labeled, and run on a 2% agarose gel containing 5µg/ml ethidium bromide. The gel was then dried and exposed to Kodak film. The formation of DNA ladders, a hallmark of apoptosis, was observed in BT474 breast tumor cells treated with 10µg/ml MAb 7C2 or MAb 4D5 for 3 days.

20 **Electron micrography studies.** BT474 cells were treated with 10µg/ml MAb 7C2 for 3 days, then fixed in 1.25% formaldehyde/1% glutaraldehyde in 0.1M cacodylate buffer. Post-fixation was performed in 2% osmium tetroxide in cacodylate buffer. The fixed cells were then end-block stained in uranyl acetate, dehydrated in graded concentrations of ethanol, and embedded in Eponet. Sections were cut utilizing a microtome and observed under a Philips CM12™ electron microscope. Highly shrunken cells displaying nuclear and cytoplasmic condensation, typical of apoptotic cells, were observed after treatment with MAb 7C2. The apoptotic cells eventually become phagocytosed by underlying cells.

25 30 The results of the experiments performed are shown in Figs. 5-14. Certain anti-ErbB2 MAbs induce apoptosis in human tumor cell lines which overexpress ErbB2 as evidenced by

electron microscopy, annexin-V binding, cell cycle analysis of DNA content, DNA laddering and time-lapse videomicrography. Anti-ErbB2 MAbs 7C2 and 7F3, which recognize the same epitope on the ErbB2 extracellular domain, display the most potent pro-apoptotic effects. Anti-ErbB2 MAb 4D5, which recognizes a different ErbB2 epitope, induces a small amount of apoptosis in addition to its potent reduction in proliferation. Induction of apoptotic cell death by 7C2 or 4D5 appears to be independent of cell cycle. Inhibition of growth, either by serum deprivation or by treatment with 4D5, followed by treatment with 7C2 can result in complete cell death of the culture.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT: Fendly, Brian M.  
Phillips, Gail D.  
Scheuermann, Richard H.  
Uhr, Jonathan W.

(ii) TITLE OF INVENTION: Anti-ErbB2 Antibodies

(iii) NUMBER OF SEQUENCES: 9

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: Genentech, Inc.  
(B) STREET: 1 DNA Way  
(C) CITY: South San Francisco  
(D) STATE: California  
(E) COUNTRY: USA  
(F) ZIP: 94080

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk  
(B) COMPUTER: IBM PC compatible  
(C) OPERATING SYSTEM: PC-DOS/MS-DOS  
(D) SOFTWARE: WinPatin (Genentech)

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER:  
(B) FILING DATE:  
(C) CLASSIFICATION:

(vii) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER: 60/028811  
(B) FILING DATE: 10/18/96

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Lee, Wendy M.  
(B) REGISTRATION NUMBER: 40,378  
(C) REFERENCE/DOCKET NUMBER: P1053R1

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: 650/225-1994  
(B) TELEFAX: 650/952-9881

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 166 amino acids  
(B) TYPE: Amino Acid  
(D) TOPOLOGY: Linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

Cys Thr Gly Thr Asp Met Lys Leu Arg Leu Pro Ala Ser Pro Glu  
1 5 10 15

Thr His Leu Asp Met Leu Arg His Leu Tyr Gln Gly Cys Gln Val  
                   20                 25                 30  
 Val Gln Gly Asn Leu Glu Leu Thr Tyr Leu Pro Thr Asn Ala Ser  
                   35                 40                 45  
 Leu Ser Phe Leu Gln Asp Ile Gln Glu Val Gln Gly Tyr Val Leu  
                   50                 55                 60  
 Ile Ala His Asn Gln Val Arg Gln Val Pro Leu Gln Arg Leu Arg  
                   65                 70                 75  
 Ile Val Arg Gly Thr Gln Leu Phe Glu Asp Asn Tyr Ala Leu Ala  
                   80                 85                 90  
 Val Leu Asp Asn Gly Asp Pro Leu Asn Asn Thr Thr Pro Val Thr  
                   95                 100                105  
 Gly Ala Ser Pro Gly Gly Leu Arg Glu Leu Gln Leu Arg Ser Leu  
                   110                115                120  
 Thr Glu Ile Leu Lys Gly Gly Val Leu Ile Gln Arg Asn Pro Gln  
                   125                130                135  
 Leu Cys Tyr Gln Asp Thr Ile Leu Trp Lys Asp Ile Phe His Lys  
                   140                145                150  
 Asn Asn Gln Leu Ala Leu Thr Leu Ile Asp Thr Asn Arg Ser Arg  
                   155                160                165  
 Ala  
 166

(2) INFORMATION FOR SEQ ID NO:2:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 32 amino acids
  - (B) TYPE: Amino Acid
  - (D) TOPOLOGY: Linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Ser Thr Gln Val Cys Thr Gly Thr Asp Met Lys Leu Arg Leu Pro  
   1                 5                 10                 15  
 Ala Ser Pro Glu Thr His Leu Asp Met Leu Arg His Leu Tyr Gln  
   20                25                 30  
 Gly Cys  
   32

(2) INFORMATION FOR SEQ ID NO:3:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 59 amino acids
  - (B) TYPE: Amino Acid

(D) TOPOLOGY: Linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

Val Glu Glu Cys Arg Val Leu Gln Gly Leu Pro Arg Glu Tyr Val  
1 5 10 15

Asn Ala Arg His Cys Leu Pro Cys His Pro Glu Cys Gln Pro Gln  
20 25 30

Asn Gly Ser Val Thr Cys Phe Gly Pro Glu Ala Asp Gln Cys Val  
35 40 45

Ala Cys Ala His Tyr Lys Asp Pro Pro Phe Cys Val Ala Arg  
50 55 59

(2) INFORMATION FOR SEQ ID NO:4:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 65 amino acids  
(B) TYPE: Amino Acid  
(D) TOPOLOGY: Linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Leu Pro Cys His Pro Glu Cys Gln Pro Gln Asn Gly Ser Val Thr  
1 5 10 15

Cys Phe Gly Pro Glu Ala Asp Gln Cys Val Ala Cys Ala His Tyr  
20 25 30

Lys Asp Pro Pro Phe Cys Val Ala Arg Cys Pro Ser Gly Val Lys  
35 40 45

Pro Asp Leu Ser Tyr Met Pro Ile Trp Lys Phe Pro Asp Glu Glu  
50 55 60

Gly Ala Cys Gln Pro  
65

(2) INFORMATION FOR SEQ ID NO:5:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 11 amino acids  
(B) TYPE: Amino Acid  
(D) TOPOLOGY: Linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

Pro Lys Asn Ser Ser Met Ile Ser Asn Thr Pro  
1 5 10 11

(2) INFORMATION FOR SEQ ID NO:6:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 7 amino acids

- (B) TYPE: Amino Acid
- (D) TOPOLOGY: Linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

His Gln Ser Leu Gly Thr Gln  
1 5 7

(2) INFORMATION FOR SEQ ID NO:7:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 8 amino acids
  - (B) TYPE: Amino Acid
  - (D) TOPOLOGY: Linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

His Gln Asn Leu Ser Asp Gly Lys  
1 5 8

(2) INFORMATION FOR SEQ ID NO:8:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 8 amino acids
  - (B) TYPE: Amino Acid
  - (D) TOPOLOGY: Linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

His Gln Asn Ile Ser Asp Gly Lys  
1 5 8

(2) INFORMATION FOR SEQ ID NO:9:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 8 amino acids
  - (B) TYPE: Amino Acid
  - (D) TOPOLOGY: Linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

Val Ile Ser Ser His Leu Gly Gln  
1 5 8

**WHAT IS CLAIMED IS:**

1. An isolated antibody which binds to Domain 1 of ErbB2.
2. The antibody of claim 1 which binds to epitope 7C2/7F3 on ErbB2.
3. The antibody of claim 1 which induces death of a cell which overexpresses ErbB2.
4. The antibody of claim 3 which induces cell death via apoptosis.
5. The antibody of claim 1 which is a monoclonal antibody.
6. The antibody of claim 1 which has nonhuman complementarity determining region (CDR) residues and human framework region (FR) residues.
7. The antibody of claim 1 which is labelled.
8. The antibody of claim 1 which is immobilized on a solid phase.
9. An isolated antibody which binds to ErbB2 and induces apoptosis of a cell which overexpresses ErbB2.
10. The antibody of claim 9 wherein the cell is a BT474 cell.
11. The antibody of claim 9 wherein the cell is a SKBR3 cell.
12. The antibody of claim 9 wherein the cell is a Calu 3 cell.
13. The antibody of claim 1 which has complementarity determining regions (CDRs) of antibody 7C2 .
14. The antibody of claim 1 which has complementarity determining regions (CDRs) of antibody 7F3.

15. A composition comprising the antibody of claim 1 and a pharmaceutically acceptable carrier.
16. The composition of claim 15 further comprising a second anti-ErbB2 antibody which does not bind to Domain 1 of ErbB2.
17. The composition of claim 15 further comprising a second antibody which binds ErbB2 and inhibits growth of SKBR3 cells in cell culture by 50-100%.
18. The composition of claim 17 wherein the second antibody binds to epitope 4D5 on ErbB2.
19. The composition of claim 18 wherein the second antibody has complementarity determining regions (CDRs) of antibody 4D5.
20. The composition of claim 15 that is sterile.
21. Nucleic acid encoding the antibody of claim 1.
22. A vector comprising the nucleic acid of claim 21.
23. A host cell comprising the nucleic acid of claim 21.
24. The host cell of claim 23 which is a hybridoma cell line producing antibody 7C2 or 7F3.
25. A method for making an anti-ErbB2 antibody comprising culturing the host cell of claim 23 so that the anti-ErbB2 antibody is expressed and recovering the anti-ErbB2 antibody from the host cell culture.
26. A method for determining the presence of ErbB2 comprising exposing a cell suspected of containing ErbB2 to the antibody of claim 1 and determining binding of said antibody to the cell.

27. A kit comprising the antibody of claim 1 and instructions for using the antibody to detect ErbB2.
28. A method for inducing cell death comprising exposing a cell which overexpresses ErbB2 to an effective amount of the antibody of claim 1.
29. The method of claim 28 wherein the cell is a cancer cell.
30. The method of claim 28 wherein the cell is in a mammal.
31. The method of claim 30 wherein the mammal is a human.
32. The method of claim 28 further comprising exposing the cell to a second anti-ErbB2 antibody which does not bind to Domain 1 of ErbB2.
33. The method of claim 28 further comprising exposing the cell to a second antibody which binds ErbB2 and inhibits growth of SKBR3 cells in cell culture by 50-100%.
34. The method of claim 33 wherein the second antibody binds to epitope 4D5 on ErbB2.
35. The method of claim 34 wherein the second antibody has complementarity determining regions (CDRs) of antibody 4D5.
36. The method of claim 28 further comprising exposing the cell to a growth inhibitory agent.
37. The method of claim 36 wherein the cell is exposed to the growth inhibitory agent prior to exposure to the antibody.
38. The method of claim 28 further comprising exposing the cell to a chemotherapeutic agent.
39. The method of claim 28 further comprising exposing the cell to radiation.

40. A method for inducing cell death comprising exposing a cell which overexpresses ErbB2 to an effective amount of the antibody of claim 9.

41. An article of manufacture, comprising:

a container;


a label on the container; and

a composition comprising an active agent contained within the container; wherein the composition is effective for inducing cell death, the label on the container indicates that the composition can be used for treating conditions characterized by overexpression of ErbB2 and the active agent in the composition is the antibody of claim 1.


## **ANTI-ErbB2 ANTIBODIES**

### **Abstract of the Disclosure**

Anti-ErbB2 antibodies are described which bind to an epitope in Domain 1 of ErbB2 and induce cell death via apoptosis. Various uses for these antibodies are also described.



**FIG. 1A**



**FIG. 1B**










FIG. 2







**FIG. 4A**




**FIG. 4B**




**FIG. 5A**




**FIG. 5B**




**FIG. 5C**



**FIG. 5D**



**FIG. 5E**



**FIG. 5F**




FIG. 6




FIG. 7A






FIG. 7B



**FIG. 8A**



**FIG. 8B**




FIG. 8C




FIG. 8D

abnormalities in the brain and spinal cord. These abnormalities include gliosis, microhemorrhage, and perivascular edema.







FIG. 8E




**FIG. 9A**




**FIG. 9B**




**FIG. 9C**




**FIG. 9D**




**FIG. 9E**




**FIG. 9F**



**FIG. 9G**




**FIG. 9H**




**FIG. 9I**


**FIG. 10A**




**FIG. 10B**



**FIG. 10C**




**FIG. 10D**





**FIG. 10E**




**FIG. 10F**






1 MELAALCRWGLLLALLPPGAASTQVCTGTD**T**MKLRLPA  
38 SPETHLDMLRHLY**Y**OGCOVVQGNLELTYLPTNASLSFL  
75 ODIOEV**Y**GYVLIAHNOVRQVPLORL**R**IVRG**T**O**L**FEDN  
112 YALAVLDNGDPLNNNTTPVTGASPGGLRELOLRSLTEI  
149 LKGGVLIORNPOLCYQDTILWKDIFHKNNOLALTLID  
186 TNRSRA


**FIG. 12**




**FIG. 13**




**FIG. 14A**



**FIG. 14B**




**FIG. 14C**



**FIG. 14D**

đóng đóng



**FIG. 14E**

**COMBINED DECLARATION FOR PATENT APPLICATION  
AND POWER OF ATTORNEY**

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

**ANTI-ErbB2 ANTIBODIES**

the specification of which (check one) \_ is attached hereto or X was filed on 09 October 1997 as Application Serial No. 08/948,192 and was amended on (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, Section 1.56.

---

I hereby claim foreign priority benefits under Title 35, United States Code, §119(a)-(d) of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate have a filing date before that of the application on which priority is claimed:

| Prior Foreign Application(s):   |         | Priority Claimed       |
|---|---------|------------------------|
|   |         | <u>Yes</u> <u>No</u>   |
| Number  | Country | Day/Month/Year Filed   |
| I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional applications(s) listed below: |         |                        |
| <u>60/028,811</u>   |         | <u>18 October 1996</u> |
| Application Ser. No.  |         | Filing Date            |

---

I hereby claim the benefit under Title 35, United States Code, §120 of any United States applications(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

|                      |             |                                      |
|----------------------|-------------|--------------------------------------|
| Application Ser. No. | Filing Date | Status: Patented, Pending, Abandoned |
| Application Ser. No. | Filing Date | Status: Patented, Pending, Abandoned |

---

**POWER OF ATTORNEY:** As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

|                                      |                                       |
|--------------------------------------|---------------------------------------|
| Walter E. Buting - Reg. No. 23,092   | Wendy M. Lee - Reg. No. 40,378        |
| Deirdre L. Conley - Reg. No. 36,487  | Richard B. Love - Reg. No. 34,659     |
| Ginger R. Dreger - Reg. No. 33,055   | Diane L. Marschang - Reg. No. 35,600  |
| Janet E. Hasak - Reg. No. 28,616     | Timothy R. Schwartz - Reg. No. 32,171 |
| Sean A. Johnston - Reg. No. 35,910   | Craig G. Svoboda - Reg. No. 39,044    |
| Dennis G. Kleid - Reg. No. 32,037    | Timothy E. Torchia - Reg. No. 36,700  |
| Jeffrey S. Kubinec - Reg. No. 36,575 | Daryl B. Winter - Reg. No. 32,637     |

Send correspondence to Genentech, Inc.

Attn: Wendy M. Lee  
1 DNA Way  
South San Francisco, CA 94080  
Telephone: (650) 225-1994


I hereby declare that all statements made herein of my own knowledge and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment or both, under Section 1001 of Title 18 of the United States Code and that willful false statements may jeopardize the validity of the application or any patent issued thereon.

The undersigned hereby authorizes the U.S. attorney or agent named herein to accept and follow instructions from his foreign patent agent as to any action to be taken in the Patent and Trademark Office regarding this application without direct communication between the U.S. attorney or agent and the undersigned. In the event of a change in the persons from whom instructions may be taken, the U.S. attorney or agent named herein will be so notified by the undersigned.

Full name of sole or first inventor

Brian M. Fendly

Inventor's signature



Date

13 January 1998

Residence

125 Treen Way, Half Moon Bay, California 94019 USA  
One Johnson Pier, Box 8 (RM)

Citizenship

U.S.A.

Post Office Address

1 DNA Way  
South San Francisco, CA 94080

Full name of second joint inventor, if any

Gail Dianne Phillips

Inventor's signature



Date

Jan. 14, 1998

Residence

515 De Anza Ave., San Carlos, California, 94070 USA

Citizenship

U.S.A.

Post Office Address

1 DNA Way  
South San Francisco, CA 94080

---

Full name of third joint inventor, if any

Richard H. Scheuermann

Inventor's signature



Date

1/15/98

Residence

3703 Poplar Court, Carrollton, TX 75007 USA

Citizenship  
U.S.A.

Post Office Address

1 DNA Way  
South San Francisco, CA 94080

---

Full name of fourth joint inventor, if any

Jonathan W. Uhr, M.D.

Inventor's signature



Date

1-15-98

Residence

2311 Shiremont, Dallas, TX USA

Citizenship  
U.S.A.

Post Office Address

1 DNA Way  
South San Francisco, CA 94080

---